UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

~~QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

~~For~~For the quarterly periodended ~~June 30, 2021~~March 31, 2022

☐	☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

~~For the transition period from ______ to _____~~

~~Commission~~Forthetransitionperiodfromto

Commission File Number: 001-36833

VOLITIONRX LIMITED

(Exact name of registrant as specified in its charter)

Delaware

91-1949078

(State or other jurisdiction of ~~incorporation~~

incorporation or organization)

(I.R.S. Employer

Identification No.)

13215 Bee Cave Parkway

Suite 125, Galleria Oaks B

Austin,, Texas 78738

~~(Address~~ (Address of principal executive offices)

+1 (646) ~~650-1351~~650–1351

(~~Registrant's~~Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which

Registered

Common Stock, par value $0.001 per share

VNRX

NYSE American, LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of ~~"large~~“large accelerated filer,~~" "accelerated~~” “accelerated filer,~~" "smaller~~” “smaller reporting company,"” and ~~"emerging~~“emerging growth ~~company"~~company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated ~~filer~~Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒No

As of ~~August~~May 5, ~~2021,~~2022, there were ~~53,145,239~~53,846,973 shares of the ~~registrant's~~registrant’s $0.001 par value common stock issued and outstanding.

VOLITIONRX LIMITED

QUARTERLY REPORT ON FORM 10-Q

FOR THE THREE ~~AND SIX~~ MONTHS ENDED ~~JUNE 30, 2021~~MARCH 31, 2022

~~TABL~~ETABLE OF CONTENTS

Use of Terms

Except as otherwise indicated by the context, references in this Quarterly Report on Form 10-Q to the ~~"Company," "VolitionRx," "Volition," "we," "us,"~~“Company,” “VolitionRx,” “Volition,” “we,” “us,” and ~~"our"~~“our” are references to VolitionRx Limited and its ~~wholly-owned~~wholly owned subsidiaries, Volition Global Services SRL, Singapore Volition Pte. Limited, Belgian Volition SRL, Volition Diagnostics UK Limited, Volition America, Inc., Volition Germany GmbH, and its majority-owned subsidiary, Volition Veterinary Diagnostics Development LLC. Additionally, unless otherwise specified, all references to ~~"$"~~“$” refer to the legal currency of the United States of America.

Nucleosomics^TM and Nu.Q^® and their respective logos are trademarks and/or service marks of VolitionRx and its subsidiaries. All other trademarks, service marks and trade names referred to herein are the property of their respective owners.

Table ofOf Contents

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q for the quarterly period ended ~~June 30, 2021,~~March 31, 2022, or this Report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this Report or incorporated by reference into this Report are forward-looking statements. These statements include, among other things, ~~any~~ predictions of earnings, revenues, expenses or other financial items; plans or expectations with respect to our development activities or business strategy; statements concerning clinical studies and results; statements concerning industry trends; statements regarding anticipated demand for our products, or the products of our competitors; statements relating to manufacturing forecasts, and the potential impact of our relationship with contract manufacturers and original equipment manufacturers on our business; statements relating to the commercialization of our products, assumptions regarding the future cost and potential benefits of our research and development efforts; forecasts of our liquidity position or available cash resources; statements relating to the impact of pending litigation; statements regarding the anticipated impact of the COVID-19 pandemic and statements relating to the assumptions underlying any of the foregoing. Throughout this Report, we have attempted to identify forward-looking statements by using words such as ~~"may," "believe," "will," "could," "project," "anticipate," "expect," "estimate," "should," "continue," "potential," "plan," "forecasts," "goal," "seek," "intend,"~~“may,” “believe,” “will,” “could,” “project,” “anticipate,” “expect,” “estimate,” “should,” “continue,” “potential,” “plan,” “forecasts,” “goal,” “seek,” “intend,” other forms of these words or similar words or expressions or the negative thereof (although not all forward-looking statements contain these words).

We have based our forward-looking statements on our current expectations and projections about trends affecting our business and industry and other future events. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Forward-looking statements are subject to substantial risks and uncertainties that could cause our future business, financial condition, results of operations or performance, to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this Report. ~~For instance, if we fail to develop~~

Some significant factors that may impact our estimates and ~~commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties~~forward-looking statements include, ~~those associated with:~~but are not limited to:

	·	~~the COVID-19 pandemic;~~Our inability to generate any significant revenue or achieve profitability;
	·	Our need to raise additional capital in the future;
	·	Our expectations to expand our ~~failure~~product development, research and sales and marketing capabilities could give rise to difficulties in managing our growth;
	·	Our limited experience with direct sales and marketing;
	·	The material weaknesses in our internal control over financial reporting that we have identified;
	·	The possibility that we may not be able to continue to operate, as indicated by the “going concern” opinion from our auditors;
	·	Our ability to successfully develop, manufacture, market, and sell our future products;
	·	Our ability to timely obtain necessary regulatory clearances or approvals to distribute and market our future ~~products in the veterinary or clinical in-vitro diagnostics, or IVD, market;~~products;
	·	~~a failure by the marketplace to accept the products in our development pipeline or any other diagnostic products we might develop;~~
	·	The acceptance by the marketplace of our ~~failure to secure adequate intellectual property protection;~~future products;
	·	~~the potential obsolescence of our intended products due to the~~The highly competitive and rapidly changing nature of the cancer diagnostics ~~market and its rapid technological change; and~~market;
	·	Our reliance on third parties to manufacture and supply our intended products, and such manufacturers’ dependence on third-party suppliers;
	·	Our dependence on third-party distributors;
	·	Protection of our patents, intellectual property and trade secrets;
	·	Business disruptions and economic and other uncertainties surrounding the COVID-19 pandemic; and
	·	Other risks identified elsewhere in this Report, as well as in our other filings with the Securities and Exchange Commission, or the SEC.

In addition, actual results may differ as a result of additional risks and uncertainties of which we are currently unaware or which we do not currently view as material to our business. For these reasons, readers are cautioned not to place undue reliance on any forward-looking statements. Our actual financial condition and results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed in the sections entitled ~~"Management's~~“Management’s Discussion and Analysis of Financial Condition and Results of ~~Operations"~~Operations” and ~~"Risk Factors"~~“Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2020~~2021, as filed with the SEC on March ~~22, 2021~~30, 2022, or our Annual Report, this Report, the documents that we file as exhibits to this Report and the documents that we incorporate by reference into this Report, with the understanding that our future results may be materially different from what we currently expect. The forward-looking statements we make speak only as of the date on which they are made. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations. If we do update or correct any forward-looking statements, readers should not conclude that we will make additional updates or corrections.

Table ofOf Contents

~~PAR~~~~T I - FINANCIAL INFORMATION~~

~~ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)~~

PART I FINANCIAL INFORMATION
~~Page~~ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
	Page

Condensed Consolidated Balance Sheets		5
Condensed Consolidated Statements of Operations and Comprehensive Loss		6
Condensed Consolidated Statements of Stockholders’ Equity		7
Condensed Consolidated Statements of Cash Flows		9	8
Notes to the Condensed Consolidated Financial Statements		10	9

Table ofOf Contents

VOLITIONRX LIMITED

~~Condensed~~Condensed Consolidated Balance Sheets

(Expressed in United States Dollars, except share numbers)

	June 30,		December 31,			March 31,			December 31,
	2021		2020			2022			2021
	$		$			$			$
ASSETS	(UNAUDITED)					(UNAUDITED)

Current Assets
Cash and cash equivalents		27,913,169		19,444,737			23,732,379			20,581,313
Accounts receivable		15,832		7,118			72,371			12,510
Prepaid expenses		935,498		303,178			1,263,149			598,367
Other current assets		527,827		576,660			888,827			786,642
Total Current Assets		29,392,326		20,331,693			25,956,726			21,978,832

Property and equipment, net		5,266,646		5,171,134			4,721,065			4,911,077
Operating lease right-of-use assets		318,393		326,085			830,257			383,551
Intangible assets, net		266,586		321,641			175,391			216,876
Total Assets		35,243,951		26,150,553			31,683,439			27,490,336

LIABILITIES AND STOCKHOLDERS' EQUITY
LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities
Accounts payable		1,083,214		1,539,547			2,205,240			1,542,457
Accrued liabilities		3,152,019		3,491,740			3,538,881			3,828,501
Management and directors' fees payable		91,695		55,174
Deferred revenue							10,000,000			12,512
Management and directors’ fees payable							97,640			71,303
Current portion of long-term debt		822,369		841,319			1,333,316			797,855
Current portion of finance lease liabilities		55,335		59,930			46,656			48,958
Current portion of operating lease liabilities		157,911		179,624			249,051			171,166
Current portion of grant repayable		35,554		69,218			42,036			43,100
Total Current Liabilities		5,398,097		6,236,552			17,512,820			6,515,852

Long-term debt, net of current portion		2,219,748		2,606,885			2,031,875			2,270,767
Finance lease liabilities, net of current portion		557,338		601,967			486,690			511,086
Operating lease liabilities, net of current portion		166,085		151,828			594,392			217,305
Grant repayable, net of current portion		273,138		259,603			246,970			253,221
Total Liabilities		8,614,406		9,856,835			20,872,747			9,768,231

STOCKHOLDERS' EQUITY

STOCKHOLDERS’ EQUITY
Common Stock
Authorized: 100,000,000 shares of common stock, at $0.001 par value
Issued and outstanding: 53,144,082 shares and 48,607,017 shares, respectively		53,144		48,607
Issued and outstanding: 53,790,261 shares and 53,772,261 shares, respectively							53,790			53,772
Additional paid-in capital		148,468,001		126,526,239			155,655,418			154,730,938
Accumulated other comprehensive income (loss)		29,607		(59,978)
Accumulated other comprehensive income							30,422			148,326
Accumulated deficit		(121,817,065)		(110,173,971)			(144,622,666	)		(136,988,636	)
Total VolitionRx Limited Stockholders' Equity		26,733,687		16,340,897
Total VolitionRx Limited Stockholders’ Equity							11,116,964			17,944,400
Non-controlling interest		(104,142)		(47,179)			(306,272	)		(222,295	)
Total Stockholders' Equity		26,629,545		16,293,718
Total Stockholders’ Equity							10,810,692			17,722,105

Total Liabilities and Stockholders' Equity		35,243,951		26,150,553
Total Liabilities and Stockholders’ Equity							31,683,439			27,490,336

(The accompanying notes are an integral part of these condensed consolidated financial statements)					(The accompanying notes are an integral part of these condensed consolidated financial statements)

~~(The accompanying notes are an integral part of these condensed consolidated financial statements)~~

Table ofOf Contents

~~VOLITIONRX~~VOLITIONRX LIMITED

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

(Expressed in United States Dollars, except share numbers)

	Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended March 31,
	2021		2020		2021		2020			2022			2021
	$		$		$		$			$			$
Revenues
Royalty		0		1,872		0		2,112
Services											60,254			0
Product		24,782		3,322		50,312		3,626			53,957			25,530
Total Revenues		24,782		5,194		50,312		5,738			114,211			25,530

Operating Expenses
Research and development		3,649,469		3,492,845		7,522,547		7,387,811			3,590,053			3,873,079
General and administrative		1,816,599		1,508,836		3,626,759		3,212,358			2,602,152			1,810,160
Sales and marketing		459,371		215,891		886,772		489,845			1,598,983			427,401
Total Operating Expenses		5,925,439		5,217,572		12,036,078		11,090,014			7,791,188			6,110,640

Operating Loss		(5,900,657)		(5,212,378)		(11,985,766)		(11,084,276)			(7,676,977	)		(6,085,110	)

Other Income (Expenses)
Grant income		391,532		90,946		391,532		98,870
(Loss) / Gain on disposal of fixed assets		(26,166)		93,202		(26,167)		93,202
Interest income		492		7,741		2,213		46,155			2			1,721
Interest expense		(39,688)		(22,604)		(81,869)		(56,383)			(41,032	)		(42,181	)

Total Other Income (Expenses)		326,170		169,285		285,709		181,844			(41,030	)		(40,460	)

Net Loss		(5,574,487)		(5,043,093)		(11,700,057)		(10,902,432)			(7,718,007	)		(6,125,570	)
Net Loss attributable to Non-Controlling Interest		47,539		5,779		56,963		15,346			83,977			9,424
Net Loss attributable to VolitionRx Limited Stockholders		(5,526,948)		(5,037,314)		(11,643,094)		(10,887,086)			(7,634,030	)		(6,116,146	)

Other Comprehensive Income (Loss)
Other Comprehensive (Loss) / Income
Foreign currency translation adjustments		(44,548)		(74,320)		89,585		299,606			(117,904	)		134,133
											��
Net Comprehensive Loss		(5,619,035)		(5,117,413)		(11,610,472)		(10,602,826)			(7,835,911	)		(5,991,437	)

Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited		(0.10)		(0.12)		(0.22)		(0.26)
Net Loss Per Share – Basic and Diluted											(0.14	)		(0.12	)
Weighted Average Shares Outstanding
– Basic and Diluted											53,775,096			50,928,742

Weighted Average Shares Outstanding
- Basic and Diluted		52,947,173		43,414,318		51,943,534		42,312,172
(The accompanying notes are an integral part of these condensed consolidated financial statements)									(The accompanying notes are an integral part of these condensed consolidated financial statements)

~~(The accompanying notes are an integral part of these condensed consolidated financial statements)~~

Table ofOf Contents

VOLITIONRX LIMITED

Condensed Consolidated Statements of ~~Stockholders'~~Stockholders’ Equity (Unaudited)

(Expressed in United States Dollars, except share numbers)

Accumulated

Additional

Other

Non

Common Stock

Paid-in

Comprehensive

Accumulated

Controlling

Shares

Amount

Capital

Income (Loss)

Deficit

Interest

Total

#

$

$

$

$

$

$

Balance, December 31, 2020

48,607,017

48,607

126,526,239

(59,978)

(110,173,971)

(47,179)

16,293,718

Common stock issued for cash

4,183,533

4,184

20,324,744

0

0

0

20,328,928

Common stock issued for cashless exercise of stock options and settlement of RSUs

80,451

80

(80)

0

0

0

0

Stock-based compensation

-

0

555,342

0

0

0

555,342

Tax withholdings paid related to stock-based compensation

-

0

(23,758)

0

0

0

(23,758)
Foreign currency translation

-

0

0

134,133

0

0

134,133

Net loss for the period

-

0

0

0

(6,116,146)

(9,424)

(6,125,570)

Balance, March 31, 2021

52,871,001

52,871

147,382,487

74,155

(116,290,117)

(56,603)

31,162,793

Common stock issued for cash

251,369

251

854,460

0

0

0

854,711

Common stock issued for cashless exercise of stock options and settlement of RSUs

21,712

22

(22)

0

0

0

0

Stock-based compensation

-

0

337,744

0

0

0

337,744

Tax withholdings paid related to stock-based compensation

-

0

(106,668)

0

0

0

(106,668)
Foreign currency translation

-

0

0

(44,548)

0

0

(44,548)
Net loss for the period

-

0

0

0

(5,526,948)

(47,539)

(5,574,487)

Balance, June 30, 2021

53,144,082

53,144

148,468,001

29,607

(121,817,065)

(104,142)

26,629,545

~~(The accompanying notes are an integral part of these condensed consolidated financial statements)~~

								Accumulated
					Additional			Other						Non
	Common Stock				Paid-in			Comprehensive			Accumulated			Controlling
	Shares		Amount		Capital			Income (Loss)			Deficit			Interest			Total
	#		$		$			$			$			$			$
Balance, December 31, 2021		53,772,261		53,772		154,730,938			148,326			(136,988,636	)		(222,295	)		17,722,105
Common stock issued for cash		3,000		3		9,464			0			0			0			9,467
Common stock issued for settlement of RSUs		15,000		15		(15	)		0			0			0			0
Stock-based compensation		-		0		915,031			0			0			0			915,031
Foreign currency translation		-		0		0			(117,904	)		0			0			(117,904	)
Net loss for the period		-		0		0			0			(7,634,030	)		(83,977	)		(7,718,007	)
Balance, March 31, 2022		53,790,261		53,790		155,655,418			30,422			(144,622,666	)		(306,272	)		10,810,692

Balance, December 31, 2020		48,607,017		48,607		126,526,239			(59,978	)		(110,173,971	)		(47,179	)		16,293,718

Common stock issued for cash		4,183,533		4,184		20,324,744			0			0			0			20,328,928
Common stock issued for cashless exercise of stock options and settlement of RSUs		80,451		80		(80	)		0			0			0			0
Stock-based compensation		-		0		555,342			0			0			0			555,342
Tax withholdings paid related to stock-based compensation		-		0		(23,758	)		0			0			0			(23,758	)
Foreign currency translation		-		0		0			134,133			0			0			134,133
Net loss for the period		-		0		0			0			(6,116,146	)		(9,424	)		(6,125,570	)
Balance, March 31, 2021		52,871,001		52,871		147,382,487			74,155			(116,290,117	)		(56,603	)		31,162,793

(The accompanying notes are an integral part of these condensed consolidated financial statements)

Table ofOf Contents

~~VOLITIONRX~~VOLITIONRX LIMITED

Condensed Consolidated Statements of ~~Stockholders' Equity~~Cash Flows (Unaudited)

(Expressed in United States ~~Dollars, except share numbers)~~Dollars)

Accumulated

Additional

Other

Non

Common Stock

Paid-in

Comprehensive

Accumulated

Controlling

Shares

Amount

Capital

Income (Loss)

Deficit

Interest

Total

#

$

$

$

$

$

$
Balance, December 31, 2019

41,125,303

41,125

103,853,627

125,670

(89,821,856)

0

14,198,566

Common stock issued for Director compensation in Volition Germany

73,263

73

333,896

0

0

0

333,969

Common stock issued for cashless exercise of stock options

19,430

20

(20)

0

0

0

0

Stock-based compensation

-

0

192,669

0

0

0

192,669

Stock repurchase

(11,364)

(11)

(54,423)

0

0

0

(54,434)
Foreign currency translation

-

0

0

373,926

0

0

373,926

Net loss for the period

-

0

0

0

(5,849,772)

(9,567)

(5,859,339)
Balance, March 31, 2020

41,206,632

41,207

104,325,749

499,596

(95,671,628)

(9,567)

9,185,357

Common stock issued for cash, net

5,452,922

5,453

14,229,160

0

0

0

14,234,613

Stock-based compensation

-

0

360,640

0

0

0

360,640

Foreign currency translation

-

0

0

(74,320)

0

0

(74,320)
Net loss for the period

-

0

0

0

(5,037,314)

(5,779)

(5,043,093)
Balance, June 30, 2020

46,659,554

46,660

118,915,549

425,276

(100,708,942)

(15,346)

18,663,197

~~(The accompanying notes are an integral part of these condensed consolidated financial statements)~~

	Three Months Ended March 31,
	2022			2021
	$			$
Operating Activities
Net Loss		(7,718,007	)		(6,125,570	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		224,310			227,342
Amortization of operating lease right-of-use assets		65,361			50,046
Stock-based compensation		915,031			555,342
Changes in operating assets and liabilities:
Prepaid expenses		(664,782	)		(792,793	)
Accounts receivable		(59,861	)		(14,238	)
Other current assets		(102,185	)		86,907
Deferred Revenue, current and non-current		10,000,000			0
Accounts payable and accrued liabilities		361,237			(87,002	)
Management and directors’ fees payable		25,750			(15,690	)
Right-of-use assets operating leases liabilities		(57,008	)		(49,485	)
Net Cash Provided By / (Used In) Operating Activities		2,989,846			(6,165,141	)

Investing Activities:
Purchases of property and equipment		(124,648	)		(483,940	)
Net Cash Used In Investing Activities		(124,648	)		(483,940	)

Financing Activities:
Net proceeds from issuances of common stock		9,467			20,328,928
Tax withholdings paid related to stock-based compensation		0			(23,758	)
Proceeds from long-term debt		620,549			79,590
Payments on long-term debt		(250,711	)		(161,727	)
Payments on finance lease obligations		(13,133	)		(14,722	)
Net Cash Provided By Financing Activities		366,172			20,208,311

Effect of foreign exchange on cash		(80,304	)		57,744

Net Change in Cash		3,151,066			13,616,974
Cash and cash equivalents – Beginning of Period		20,581,313			19,444,737
Cash and cash equivalents – End of Period		23,732,379			33,061,711

Supplemental Disclosures of Cash Flow Information:
Interest paid		41,032			42,181
Non-Cash Financing Activities:
Common stock issued on cashless exercises of stock options and settlement of vested RSUs		15			80
Offering costs from issuance of common stock		0			119,029

(The accompanying notes are an integral part of these condensed consolidated financial statements)

Table ofOf Contents

VOLITIONRX LIMITED

Condensed Consolidated Statements of Cash Flows (Unaudited)
(Expressed in United States Dollars)

Six Months Ended June 30,

2021

2020

$

$

Operating Activities

Net loss

(11,700,057 )

(10,902,432 )
Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

471,754

359,233

Amortization of operating lease right-of-use assets

99,035

125,871

Loss (Gain) on disposal of fixed assets

26,166

(93,202 )
Stock-based compensation

893,086

553,309

Common stock issued for Director compensation in Volition Germany

0

333,969

Changes in operating assets and liabilities:

Prepaid expenses

(632,320 )

(317,795 )
Accounts receivable

(8,682 )

(3,223 )
Other current assets

50,605

(109,213 )
Accounts payable and accrued liabilities

(630,236 )

959,425

Management and directors' fees payable

(36,791 )

(10,497 )
Right-of-use assets operating leases liabilities

(98,789 )

(125,331 )
Net Cash Used In Operating Activities

(11,566,229 )

(9,229,886 )

Investing Activities:

Purchases of property and equipment

(703,180 )

(597,366 )
Net Cash Used In Investing Activities

(703,180 )

(597,366 )

Financing Activities:

Net proceeds from issuances of common stock

21,183,639

14,234,613

Tax withholdings paid related to stock-based compensation

(130,426 )

0

Common stock repurchased

0

(54,434 )
Proceeds from grants repayable

37,672

3,802

Proceeds from long-term debt

79,614

0

Payments on long-term debt

(383,782 )

(234,172 )
Payments on grants repayable

(47,830 )

0

Payments on finance lease obligations

(29,347 )

(69,483 )
Net Cash Provided By Financing Activities

20,709,540

13,880,326

Effect of foreign exchange on cash

28,301

286,024

Net Change in Cash

8,468,432

4,339,098

Cash and cash equivalents - Beginning of Period

19,444,737

16,966,168

Cash and cash equivalents - End of Period

27,913,169

21,305,266

Supplemental Disclosures of Cash Flow Information:

Interest paid

81,869

56,383

Non-Cash Financing Activities:

Common stock issued on cashless exercises of stock options

80

20

Offering costs from issuance of common stock

119,029

1,229,169

~~(The accompanying notes are an integral part of these condensed consolidated financial statements)~~

~~Table of Contents~~

~~VOL~~~~ITIONRX LIMITED~~

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

~~Note~~Note 1 -– Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The interim consolidated financial statements of VolitionRx Limited (the ~~"Company"~~“Company”, ~~"VolitionRx," "we"~~“VolitionRx,” “we” or ~~"us"~~“us”) for the three ~~and six~~ months ended ~~June 30,~~March 31, 2022 and March 31, 2021, ~~and June 30, 2020,~~ respectively, are ~~not audited.~~unaudited. Our consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods and, consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America ("(“U.S. ~~GAAP"~~GAAP”). In the opinion of our management, the accompanying consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of our financial position as of ~~June 30, 2021,~~March 31, 2022, and our results of operations and cash flows for the periods ended ~~June 30,~~March 31, 2022 and March 31, 2021, ~~and June 30, 2020,~~ respectively. The results of operations for the periods ended ~~June 30,~~March 31, 2022 and March 31, 2021, ~~and June 30, 2020,~~ respectively, are not necessarily indicative of the results for a full-year period. These interim consolidated financial statements should be read in conjunction with the financial statements included in our Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021, which was filed with the Securities and Exchange Commission (the ~~"SEC"~~“SEC”) on March ~~22, 2021.~~

30, 2022.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances, useful lives of property and equipment and intangible assets, borrowing rate used in operating lease right-of-use asset and liability valuations, impairment analysis of intangible assets, and valuations of stock-based compensation.

The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the ~~Company's~~Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations could be affected.

Principles of Consolidation

The accompanying condensed consolidated financial statements for the period ended ~~June 30, 2021~~March 31, 2022 include the accounts of the Company and its subsidiaries. The Company has ~~one~~two wholly-owned ~~subsidiary,~~subsidiaries Singapore Volition Pte. Limited ("(“Singapore ~~Volition"~~Volition”) and Volition Global Services SRL (“Volition Global”). Singapore Volition has one wholly-owned subsidiary, Belgian Volition SRL ("(“Belgian ~~Volition"~~Volition”). Belgian Volition has four subsidiaries, Volition Diagnostics UK Limited ("(“Volition ~~Diagnostics"~~Diagnostics”), Volition America, Inc. ("(“Volition ~~America"~~America”), Volition Germany GmbH ("(“Volition ~~Germany"~~Germany”), and its one majority-owned subsidiary Volition Veterinary Diagnostics Development LLC ("(“Volition ~~Vet"~~Vet”). See Note 8(f) for more information regarding Volition Vet, Volition Germany and Volition ~~Germany.~~America. All intercompany balances and transactions have been eliminated in consolidation.

Cash and Cash Equivalents

For the purposes of the statements of cash flows, the Company considers interest bearing deposits with original maturity dates of three months or less to be cash equivalents. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the condensed consolidated balance sheets at fair value using quoted prices in active markets for identical assets. As of ~~June 30, 2021,~~March 31, 2022, cash and cash equivalents totaled approximately ~~$27.9~~$23.7 million, of which ~~$20.2~~$10.2 million was held in an overnight money market account.

109

Table ofOf Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 1 - Basis of Presentation and ~~Summary~~Summary of Significant Accounting Policies (continued)

Accounts Receivables

Trade accounts receivable are stated at the amount the Company expects to collect. Due to the nature of the accounts receivable balance, the Company believes the risk of doubtful accounts is minimal and therefore no allowance is recorded. If the financial condition of the ~~Company's~~Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. The Company may provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. As of ~~June 30, 2021,~~March 31, 2022, the accounts receivable balance was ~~$15,832~~$72,371 and the allowance for doubtful debts was $nil.

Revenue Recognition

The Company adopted Accounting Standards Codification ~~("ASC"~~(“ASC”)606, "“Revenue from Contracts with Customers,"” effective January 1, 2019. Under ASC 606, the Company recognizes revenues when the customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company recognizes revenues following the five step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) the Company satisfies the performance obligation(s).

The Company generates product revenues from the sale of its Nu.Q^® Vet Cancer Screening Test, from the sale of nucleosomes, and from the sale of Research Use Only ~~kits pursuant to its license agreement with Active Motif, Inc. ("Active Motif") from which the Company receives royalties.~~kits. In addition, revenue is received from external third parties for Nu.Q^®Discover services the Company performs for them in its laboratory.

Revenues, and their respective treatment for financial reporting purposes under ASC 606, are as follows:

Royalty

The Company receives royalty revenues on the net sales recognized during the period in which the revenue is earned, and the amount is determinable from the licensee. These are presented in ~~"Royalty"~~“Royalty” in the consolidated statements of operations and comprehensive loss. The Company does not have future performance obligations under this revenue stream. In accordance with ASC 606, the Company records these revenues based on estimates of the net sales that occurred during the relevant period from the licensee. The relevant period estimates of these royalties are based on preliminary gross sales data provided by ~~Active Motif~~Customers and analysis of historical gross-to-net adjustments. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known.

Product

The Company includes revenue from product sales recognized during the period in which goods are shipped to third parties, and the amount is deemed collectable from the third parties. These are presented in ~~"Product"~~“Product” in the consolidated statements of operations and comprehensive loss.

1110

Table ofOf Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 1 - Basis of Presentation and ~~Summary~~Summary of Significant Accounting Policies (continued)

Services

The Company includes revenue recognized from laboratory services performed in the ~~Company's~~Company’s laboratory on behalf of third parties in ~~"Services"~~“Services” in the consolidated statements of operations and comprehensive loss.

For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the ~~Company's~~Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.

Licensing

The Company includes revenue recognized from the licensing of certain rights to third parties in “Licensing” in the consolidated statements of operations. For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.

Deferred Revenue (Contract Liabilities) and Contract Assets

Deferred revenue consists of amounts for which we have an unconditional right to bill, and/or amounts for which payment has been received–including non-refundable amounts, but have not been recognized as revenue because the related performance obligations are deemed incomplete. As at March 31, 2022, the Company recorded $10.0 million as deferred revenue in respect of a non-refundable payment received in relation to a licensing and product supply agreement with Heksa Corporation. As at March 31, 2021, the Company recorded $nil deferred revenue.

Contract assets include costs and services incurred on contracts with open performance obligations. These contract assets were immaterial as of March 31, 2022.

Basic and Diluted Net Loss Per Share

The Company computes net loss per share in accordance with ASC 260, ~~"Earnings~~“Earnings Per Share,"” which requires presentation of both basic and diluted earnings per share ~~("EPS"~~(“EPS”) on the face of the statement of operations and comprehensive loss. Basic EPS is computed by dividing net loss available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. As of ~~June 30, 2021, 4,732,235~~March 31, 2022, 6,346,268 potential common shares equivalents from warrants, options, and restricted stock units ~~("RSUs"~~(“RSUs”) were excluded from the diluted EPS calculations as their effect is anti-dilutive.

Table Of Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (continued)

Foreign Currency Translation

The Company has functional currencies in Euros, US Dollars and British Pounds Sterling and its reporting currency is the US Dollar. Management has adopted ASC 830-20, “Foreign Currency Matters – Foreign Currency Transactions”. All assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. For revenues and expenses, the weighted average exchange rate for the period is used. Gains and losses arising on translation of foreign currency denominated transactions are included in other comprehensive income (loss).

Research and Development

In accordance with ASC 730, the Company follows the policy of expensing its research and development costs in the period in which they are incurred. The Company incurred research and development expenses of $3.6 million and $3.9 million during the three-months ended March 31, 2022, and March 31, 2021, respectively.

Stock-Based Compensation

The Company records stock-based compensation in accordance with ASC 718, “Compensation – Stock Compensation”. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee’s requisite service period, which is generally the vesting period. The fair value of our stock options and warrants is estimated using a Black-Scholes option valuation model. Restricted stock units are valued based on the closing stock price on the date of grant. Refer to Note 7 for further details.

Reclassification

Certain amounts presented in previously issued financial statements have been reclassified to be consistent with the current period presentation. The Company has reclassified the prior period comparative amounts in Part I, Item 2. “MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS” of the ~~statement of stockholders' equity~~Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, in relation to Research and ~~cash flows~~Development expenses, General and Administrative expenses and Sales and Marketing expenses to be consistent with the current year classification.

Recent Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect. The Company does not believe there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

~~Table of Contents~~

~~VOLITIONRX LIMITED~~

~~Notes to the Condensed Consolidated Financial Statements (Unaudited)~~

~~($ expressed in United States Dollars)~~

~~Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (continued)~~

COVID-19 Pandemic Impact

As of the date of this filing, there continue to be widespread concerns regarding the ongoing impacts and disruptions caused by the COVID-19 pandemic in the regions in which the Company operates. As a result of the COVID-19 pandemic, the Company has experienced and may continue to experience disruptions that could impact our clinical trials, including delays enrolling patients and in sample collection.

The extent to which the COVID-19 pandemic will impact the ~~Company's~~Company’s business, financial condition, and results of operations in the future is highly uncertain and will be affected by a number of factors. These include the duration and extent of the COVID-19 pandemic, the development of new variants of the COVID-19 virus that may be more contagious or virulent than previous versions, the scope of mandated or recommended containment and mitigation measures, the effect of government stabilization and recovery efforts, and the success of vaccine distribution programs.

Table Of Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 2 - Going Concern

The ~~Company's~~Company’s condensed consolidated financial statements are prepared using U.S. GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred losses since inception of ~~$121.8~~$144.6 million, has had negative cash flows from operations on an annual basis, and has minimal revenues, which creates substantial doubt about its ability to continue as a going concern for a period of at least one year from the date of issuance of these condensed consolidated financial statements.

The future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions, financing and/or to generate revenues as may be required to sustain its operations. Management plans to address the above as needed by (a) securing additional grant funds, (b) obtaining additional financing through debt or equity transactions, (c) granting licenses to third parties in exchange for specified up-front and/or ~~back-end~~milestone payments and (d) developing and commercializing its products on an accelerated timeline. Management continues to exercise tight cost controls to conserve cash.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually attain profitable operations. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

Table ofOf Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

~~Note~~Note 3 - Property and Equipment

The ~~Company's~~Company’s property and equipment consisted of the following amounts as of ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020:~~2021:

						June 30,							March 31,
						2021							2022
				Accumulated		Net Carrying					Accumulated		Net Carrying
		Cost		Depreciation		Value			Cost		Depreciation		Value
	Useful Life	$		$		$		Useful Life	$		$		$
Computer hardware and software	3 years		579,410		455,285		124,125	3 years		589,517		445,310		144,207
Laboratory equipment	5 years		3,026,194		1,271,580		1,754,614	5 years		3,019,021		1,531,605		1,487,416
Office furniture and equipment	5 years		297,841		193,087		104,754	5 years		309,799		219,544		90,255
Buildings	30 years		2,293,345		239,727		2,053,618	30 years		2,123,879		255,424		1,868,455
Building improvements	5-15 years		1,310,063		222,745		1,087,318	5-15 years		1,268,648		271,064		997,584
Land	Not amortized		142,217		0		142,217	Not amortized		133,148		0		133,148
			7,649,070		2,382,424		5,266,646			7,444,012		2,722,947		4,721,065

						December 31,							December 31,
						2020							2021
				Accumulated		Net Carrying					Accumulated		Net Carrying
		Cost		Depreciation		Value			Cost		Depreciation		Value
	Useful Life		$	$		$		Useful Life		$	$		$
Computer hardware and software	3 years		550,254		412,805		137,449	3 years		599,944		474,169		125,775
Laboratory equipment	5 years		2,586,997		1,060,153		1,526,844	5 years		3,032,108		1,434,347		1,597,761
Office furniture and equipment	5 years		271,656		171,247		100,409	5 years		293,427		213,244		80,183
Buildings	30 years		2,366,236		207,111		2,159,125	30 years		2,177,641		243,750		1,933,891
Building improvements	5-15 years		1,285,383		184,813		1,100,570	5-15 years		1,293,258		256,309		1,036,949
Land	Not amortized		146,737		0		146,737	Not amortized		136,518		0		136,518
			7,207,263		2,036,129		5,171,134			7,532,896		2,621,819		4,911,077

During the ~~six-month~~three-month periods ended ~~June 30,~~March 31, 2022 and March 31, 2021, ~~and June 30, 2020,~~ the Company recognized ~~$425,187~~$202,423 and ~~$316,405,~~$204,049, respectively, in depreciation expense.

Table ofOf Contents

~~VOL~~~~ITIONRX~~VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

~~Note~~Note 4 - Intangible Assets

The ~~Company's~~Company’s intangible assets consist of patents, mainly acquired in the acquisition of Belgian Volition. The patents are being amortized over the ~~assets'~~assets’ estimated useful lives, which range from 8 to 20 years.

					June 30,						March 31,
					2021						2022
			Accumulated		Net Carrying				Accumulated		Net Carrying
	Cost		Amortization		Value		Cost		Amortization		Value
	$		$		$		$		$		$
Patents		1,219,693		953,107		266,586		1,135,896		960,505		175,391

					December 31,						December 31,
					2020						2021
			Accumulated		Net Carrying				Accumulated		Net Carrying
	Cost		Amortization		Value		Cost		Amortization		Value
		$	$		$			$	$		$
Patents		1,256,064		934,423		321,641		1,178,135		961,259		216,876

During the ~~six-month~~three-month periods ended ~~June 30,~~March 31, 2022 and March 31, 2021, ~~and June 30, 2020,~~ the Company recognized ~~$46,567~~$21,887 and ~~$42,828,~~$23,293, respectively, in amortization expense.

The Company amortizes the patents on a straight-line basis with terms ranging from 8 to 20 years. The annual estimated amortization schedule over the next five years is as follows:

2021 - remaining	$	45,326
2022	$	91,015	$	64,991
2023	$	91,015	$	86,655
2024	$	39,230	$	23,745
2025	$	0
Total Intangible Assets	$	266,586	$	175,391

The Company periodically reviews its long-lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 Topic "“Property, Plant and ~~Equipment"~~Equipment” as of December 31, ~~2020.~~2021. The result of this review confirmed that the ongoing value of the patents was not impaired as of December 31, ~~2020.~~2021.

~~Note~~Note 5 - Related Party Transactions

~~Refer to~~See Note 6, Common Stock, for common stock issued to related parties and Note 7, Stock-Based Compensation,, for stock options, warrants and RSUs issued to related parties. The Company has agreements with related parties for the purchase of products and consultancy services which are accrued under management and ~~directors'~~directors’ fees payable (see condensed consolidated balance sheets).

Table ofOf Contents

~~VOL~~~~ITIONRX~~VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

~~Note~~Note 6 - Common Stock

As of ~~June 30, 2021,~~March 31, 2022, the Company was authorized to issue 100 million shares of common stock par value $0.001 per share, of which ~~53,144,082~~53,790,261 and ~~48,607,017~~53,772,261 shares were issued and outstanding as of ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, respectively.

Stock Option Exercises and RSU Settlements

~~From January 13, 2021 to~~On March ~~19, 2021, 7,634 stock options were exercised to purchase shares of common stock at $3.35 per share in a cashless exercise that resulted in the issuance of 948 shares of common stock.~~

~~On January 20, 2021, 5,000~~28, 2022, 15,000 RSUs vested and resulted in the issuance of ~~3,000~~15,000 shares of common ~~stock (the remaining 2,000 shares were withheld for taxes and returned as authorized shares under the 2015 Stock Incentive Plan).~~

~~On February 2, 2021, 20,000 stock options were exercised to purchase shares of common stock at $3.80 per share in a cashless exercise that resulted in the issuance of 6,181 shares of common~~ stock.

~~On February 8, 2021, 100,000 stock options were exercised to purchase shares of common stock at $5.00 per share in a cashless exercise that resulted in the issuance of 19,446 shares of common stock.~~

From February 8, 2021 to February 9, 2021, 100,000 stock options were exercised to purchase shares of common stock at $4.00 per share in cashless exercises that resulted in the issuance of 32,126 shares of common stock.

~~On February 8, 2021, 50,000 stock options were exercised to purchase shares of common stock at $3.25 per share in a cashless exercise that resulted in the issuance of 18,750 shares of common stock.~~

On April 13, 2021, 26,250 RSUs vested and resulted in the issuance of 21,712 shares of common stock (the remaining 4,538 shares were withheld for taxes and returned as authorized shares under the 2015 Stock Incentive Plan).

~~Equity~~~~Capital Raise~~

On February 10, 2021, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Cantor Fitzgerald & Co. (the "Underwriter") in connection with an underwritten public offering of 3,809,524 shares (the "Firm Shares") of the Company's common stock pursuant to the Company's shelf registration statement on Form S-3 (declared effective by the SEC on September 28, 2018, File No. 333-227248). The Underwriter purchased the Firm Shares from the Company at a price of $4.9533 per share on February 12, 2021. The net proceeds received by the Company for the sale and issuance of the Firm Shares were approximately $18.9 million. Under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for 30 days, to purchase up to an additional 571,428 shares of Common Stock at the same price per share as the Firm Shares which option was not exercised.

Equity Distribution ~~Agreements~~Agreement

On ~~November 10, 2020,~~September 24, 2021, the Company entered into an equity distribution agreement (the ~~"2020 EDA"~~“2021 EDA”) with Cantor Fitzgerald & Co. ~~("Cantor"~~Inc. (“Cantor”)and Oppenheimer & Co. Inc. ~~("Oppenheimer"~~(“Oppenheimer”), to sell shares of its common stock having an aggregate offering price of up to $25.0 million from time-to-time, through an ~~"at~~“at the market offering ~~program"~~program” pursuant to the ~~Company's~~Company’s effective ~~"shelf"~~“shelf” registration statement on Form S-3 (File No. ~~333-227248)~~333-259783) and related prospectuses, through Cantor and Oppenheimer each acting as the ~~Company's~~Company’s agent and/or principal. The Company iswas not obligated to sell any shares under the ~~2020~~2021 EDA. During the three months ended ~~June 30, 2021,~~March 31, 2022, the Company raised aggregate net proceeds (net of ~~broker's~~brokers’ commissions and fees) of ~~$857,211~~$9,464 under the ~~2020~~2021 EDA through the sale of ~~251,369~~3,000 shares of its common stock. From inception through ~~June 30, 2021,~~March 31, 2022, the Company raised aggregate net proceeds (net of ~~broker's~~brokers’ commissions and fees) of ~~$1,201,167~~approximately $0.7 million under the ~~2020~~2021 EDA through the sale of ~~316,769~~193,600 shares of its common stock.

~~Table of Contents~~

~~VOL~~~~ITIONRX LIMITED~~

~~Notes to~~ For additional information regarding the ~~Condensed Consolidated Financial Statements (Unaudited)~~

~~($ expressed in United States Dollars)~~2021 EDA, see Note 9, Subsequent Events.

~~Note 6 - Common Stock (continued)~~No

~~On September~~te 7 2018, the Company entered into an equity distribution agreement (as amended, the "2018 EDA") with Oppenheimer to sell shares of common stock having an aggregate offering price of up to $10.0 million from time-to-time, through an "at the market offering program" pursuant to the Company's effective "shelf" registration statement on Form S-3 (File No 333-227248) and related prospectuses, through Oppenheimer acting as the Company's agent and/or principal. From inception through March 31, 2021, the Company raised aggregate net proceeds (net of broker's commissions and fees) of approximately $9.7 million under the 2018 EDA through the sale of 2,539,606 shares of its common stock and fully utilized the availability under the 2018 EDA during the quarter ended March 31, 2021. No further sales will be made under the 2018 EDA.

~~Note 7 -~~– Stock-Based Compensation

a) Warrants

The following table summarizes the changes in warrants outstanding of the Company during the ~~six-month~~three-month period ended ~~June 30, 2021:~~March 31, 2022:

Number of

Weighted Average

Warrants

Exercise Price ($)

Outstanding at December 31, 2020

175,000

2.75

Granted

310,000

4.52

Outstanding at June 30, 2021

485,000

3.88

Exercisable at June 30, 2021

125,000

2.47

Effective January 1, 2021, the Company granted warrants to purchase 125,000 shares of common stock to a Company employee for services to the Company. These warrants vest on January 1, 2022 (subject to continued employment through such date) and expire on January 1, 2027, with an exercise price of $3.95 per share. The Company has calculated the estimated fair market value of these warrants at $242,877, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $3.95, exercise price $3.80, 74.53% volatility, 0.50% risk free rate, and no forfeiture rate.
Effective February 1, 2021, the Company granted warrants to purchase 185,000 shares of common stock to a Company employee for services to the Company. These warrants vest on February 1, 2022 (subject to continued employment through such date) and expire on February 1, 2027, with an exercise price of $4.90 per share. The Company has calculated the estimated fair market value of these warrants at $459,352, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $4.90, exercise price $4.80, 75.03% volatility, 0.59% risk free rate, and no forfeiture rate.

Weighted
Average

Number of
Warrants

Exercise
Price ($)

Outstanding at December 31, 2021

485,000

3.88

Granted

-

0

Outstanding at March 31, 2022

485,000

3.88

Exercisable at March 31, 2022

485,000

3.88

Below is a table summarizing the warrants issued and outstanding as of ~~June 30, 2021,~~March 31, 2022, which have an aggregate weighted average remaining contractual life of ~~4.46~~3.71 years.

Weighted Average

Remaining

Proceeds to

Number

Number

Exercise

Contractual

Company if

Outstanding

Exercisable

Price ($)

Life (Years)

Exercised ($)

125,000

125,000

2.47

0.83

308,750

50,000

-

3.45

4.67

172,500

185,000

-

4.90

5.59

906,500

125,000

-

3.95

5.51

493,750

485,000

125,000

1,881,500

Weighted Average

Remaining

Proceeds to

Number

Number

Exercise

Contractual

Company if

Outstanding

Exercisable

Price ($)

Life (Years)

Exercised ($)

125,000

125,000

2.47

0.91

308,750

50,000

50,000

3.45

3.92

172,500

125,000

125,000

3.95

4.76

493,750

185,000

185,000

4.90

4.84

906,500

485,000

485,000

1,881,500

1716
Table ofOf Contents

~~VOL~~~~ITIONRX~~VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)

~~Note~~Note 7 -– Stock-Based Compensation (continued)

a)a) Warrants (continued)

Stock-based compensation expense related to warrants of ~~$337,823~~$39,013 and ~~$41,587~~$148,364 was recorded in the ~~six~~three months ended ~~June 30,~~March 31, 2022 and March 31, 2021, ~~and June 30, 2020,~~ respectively. ~~Total~~There is no remaining ~~unrecognized compensation cost related to non-vested warrants is $402,971 and is expected~~expense to be ~~recognized over a period of 0.59 years.~~recognized. As of ~~June 30, 2021,~~March 31, 2022, the total intrinsic value of warrants outstanding was ~~$102,500.~~$67,500.
b)b) Options

The following table summarizes the changes in options outstanding of the Company during the ~~six-month~~three-month period ended ~~June 30, 2021:~~March 31, 2022:

Weighted

Average

Number of

Exercise

Options

Price ($)

Outstanding at December 31, 2020

4,278,619

4.00

Granted

40,000

3.60

Exercised

(277,634)

4.19

Outstanding at June 30, 2021

4,040,985

3.99

Exercisable at June 30, 2021

3,990,985

3.99

Weighted Average

Number of
Options

Exercise Price ($)

Outstanding at December 31, 2021

5,027,518

3.87

Granted

-

0

Exercised

-

0

Expired/Cancelled

0

0

Outstanding at March 31, 2022

5,027,518

3.87

Exercisable at March 31, 2022

3,937,518

4.00

Effective May 20, 2021, the Company granted stock options to purchase 40,000 shares of common stock to a Company employee in exchange for services provided to the Company. These options vest on May 20, 2022 and expire five years after the vesting date, with an exercise price of $3.60 per share. The Company has calculated the estimated fair market value of these options at $73,641, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $3.50, exercise price $3.60, 76.16% volatility, 0.58% risk free rate, and no forfeiture rate.
.
Below is a table summarizing the options issued and outstanding as of ~~June 30, 2021,~~March 31, 2022, all of which were issued pursuant to the 2011 Equity Incentive Plan (for option issuances prior to 2016) or the 2015 Stock Incentive Plan (for option issuances commencing in 2016) and which have an aggregate weighted average remaining contractual life of ~~2.54~~6.00 years. As of ~~June 30, 2021,~~March 31, 2022, an aggregate of 6,000,000 shares of common stock were authorized for issuance under the 2015 Stock Incentive Plan, of which ~~1,968,852~~336,352 shares of common stock remained available for future issuance thereunder.

Weighted Average

Remaining

Proceeds to

Number

Number

Exercise

Contractual

Company if

Outstanding

Exercisable

Price ($)

Life (Years)

Exercised ($)

635,000

635,000

3.25

3.62

2,063,750

2,717

2,717

3.35

0.18

9,102

10,000

-

3.40

5.42

34,000

860,000

820,000

3.60

4.85

3,096,000

1,682,837

1,682,837

4.00

1.26

6,731,348

15,268

15,268

4.35

0.65

66,416

89,163

89,163

4.38

2.57

390,534

50,000

50,000

4.80

1.51

240,000

696,000

696,000

5.00

1.74

3,480,000

4,040,985

3,990,985

16,111,150

Weighted Average

Remaining

Proceeds to

Number

Number

Exercise

Contractual

Company if

Outstanding

Exercisable

Price ($)

Life (Years)

Exercised ($)

635,000

635,000

3.25

2.87

2,063,750

2,717

2,717

3.35

1.42

9,102

1,060,000

10,000

3.40

9.35

3,604,000

800,000

760,000

3.60

8.10

2,880,000

1,682,837

1,682,837

4.00

4.51

6,731,348

11,801

11,801

4.35

1.20

51,334

89,163

89,163

4.38

5.82

390,534

50,000

50,000

4.80

4.76

240,000

696,000

696,000

5.00

4.99

3,480,000

5,027,518

3,937,518

19,450,068

1817
Table ofOf Contents

~~VOL~~~~ITIONRX~~VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)

~~Note~~Note 7 -– Stock-Based Compensation (continued)

b)b) Options (continued)

Stock-based compensation expense related to stock options of ~~$418,292~~$394,053 and ~~$482,103~~$355,076 was recorded in the ~~six~~three months ended ~~June 30,~~March 31, 2022 and March 31, 2021, ~~and June 30, 2020,~~ respectively. Total remaining unrecognized compensation cost related to non-vested stock options is ~~$72,095~~$1,064,229 and is expected to be recognized over a period of ~~0.89~~1.51 years. As of ~~June 30, 2021,~~March 31, 2022, the total intrinsic value of stock options outstanding was ~~$25,400.~~$nil.
c) Restricted Stock Units (RSUs)

Below is a table summarizing the RSUs issued and outstanding as of ~~June 30, 2021,~~March 31, 2022, all of which were issued pursuant to the 2015 Stock Incentive Plan.

Number of RSUs

Share Price ($)

Outstanding at December 31, 2020

67,500

3.47

Granted

185,000

3.37

Vested

(31,250)

3.56

Cancelled

(15,000)

3.30

Outstanding at June 30, 2021

206,250

3.38

Number of

Weighted Average

RSUs

Share Price ($)

Outstanding at December 31, 2021

810,750

3.33

Granted

38,000

2.81

Vested/Settled

(15,000 )

3.59

Cancelled

-

0

Outstanding at March 31, 2022

833,750

3.30

Effective ~~January 1, 2021,~~February 8, 2022, the Company granted aggregate RSUs of ~~5,000~~8,000 shares of common stock to ~~a Company~~an employee in exchange for services provided to the Company. These RSUs ~~vested immediately,~~vest over two years, with 50% vesting on ~~January 1, 2021~~each of February 8, 2023 and ~~resulted~~February 8, 2024, subject to continued service, and will result in ~~the issuance of 3,000 shares (the remaining 2,000 shares were withheld for taxes and returned as authorized shares under the 2015 Stock Incentive Plan) and~~ total compensation expense of ~~$19,450.~~$22,640.

Effective March ~~25, 2021,~~1, 2022, the Company granted aggregate RSUs of 30,000 shares of common stock to ~~two non-executive directors~~various employees in exchange for services provided to the Company. These RSUs vest over two years, with 50% vesting on each of March ~~25, 2022~~1, 2023 and March ~~25, 2023~~1, 2024, subject to continued service, and will result in total compensation expense of ~~$107,700.~~$84,300.

On March ~~25, 2021,~~28, 2022, 15,000 ~~RSUs previously granted to a non-executive director were cancelled and returned as authorized shares under the 2015 Stock Incentive Plan upon the resignation of such director prior to vesting.~~
~~On April 13, 2021, 26,250~~ RSUs vested and resulted in the issuance of ~~21,712 shares (the remaining 4,538 shares were withheld for taxes and returned as authorized shares under the 2015 Stock Incentive Plan).~~
~~Effective May 1, 2021, the Company granted RSUs of 150,000~~15,000 shares of common ~~stock to an employee in exchange for services provided~~stock.
18
Table Of Contents
VOLITIONRX LIMITED
Notes to the ~~Company. These~~Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 7 – Stock-based Compensation (continued)
c) Restricted Stock Units (RSUs) (continued)
Below is a table summarizing the RSUs ~~vest over three years with 50,000 units vesting on each~~issued and outstanding as of ~~May 1,~~March 31, 2022 ~~May 1, 2023~~ and ~~May 1, 2024, respectively, and will result in total~~which have an aggregate weighted average remaining contractual life of 0.92 years.

Weighted

Average

Remaining

Number

Share

Contractual

Outstanding

Price ($)

Life (Years)

30,000

2.81

1.42

8,000

2.83

1.36

39,809

3.04

1.01

610,191

3.31

0.86

38,000

3.32

0.94

23,000

3.38

1.21

43,500

3.51

1.09

26,250

3.52

0.04

15,000

3.59

0.98

833,750

Stock-based compensation expense related to RSUs of ~~$496,500~~$481,962 and $51,902 was recorded in the three months ended March 31, 2022 and March 31, 2021, respectively. Total remaining unrecognized compensation cost related to non-vested RSUs is $1,435,500. As of March 31, 2022, the total intrinsic value of the RSUs outstanding was $7,440.

19
Table ofOf Contents
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)

~~Note 7 - Stock-based Compensation (continued)~~No
~~c) Restricted Stock Units (RSUs) (continued)~~
~~Below is a table summarizing the RSUs issued and outstanding as of June 30, 2021 and which have an aggregate weighted average remaining contractual life of 1.62 years.~~

Weighted

Average

Remaining

Number

Share

Contractual

Outstanding

Price ($)

Life (Years)

150,000

3.31

1.84

26,250

3.52

0.39

30,000

3.59

1.23

206,250

Stock-based compensation expense related to RSUs of $136,971 and $29,619 was recorded in the six months ended June 30, 2021 and June 30, 2020, respectively. Total remaining unrecognized compensation cost related to non-vested RSUs is $568,243. As of June 30, 2021, the total intrinsic value of the RSUs outstanding was $nil.
~~Note~~te 8 -– Commitments and Contingencies

a) Finance Lease Obligations

In 2016, the Company entered into a ~~real estate finance~~capital lease with ING Asset Finance Belgium S.A. ~~("ING"~~(“ING”) to purchase a property located in Belgium for €1.12 million, maturing in May 2031 with implicit interest of 2.62%. As of ~~June 30, 2021,~~March 31, 2022, the balance payable was ~~$606,213.~~$533,346.

In 2018, the Company entered into a capital lease with BNP Paribas leasing solutions to purchase a freezer for the Belgium facility for €25,000, ~~maturing~~that matured in January 2022 with implicit interest of 1.35%. The leased equipment is amortized on a straight-line basis over 5 years. As of ~~June 30, 2021,~~March 31, 2022, the balance payable was ~~$6,460.~~$nil.

The following is a schedule showing the future minimum lease payments under finance leases by years and the present value of the minimum payments as of ~~June 30, 2021.~~March 31, 2022.

2021 - remaining

$ 36,917

2022

$ 65,234

$ 44,760

2023

$ 63,745

$ 59,680

2024

$ 63,744

$ 59,679

2025

$ 63,744

$ 59,679

2026

$ 59,680

Greater than 5 years

$ 406,356

$ 320,764

Total

$ 699,740

$ 604,242

Less: Amount representing interest

$ (87,067)

$ (70,896 )
Present value of minimum lease payments

$ 612,673

$ 533,346

20
~~Table of Contents~~
~~VOL~~~~ITIONRX LIMITED~~
~~Notes to the Condensed Consolidated Financial Statements (Unaudited)~~
~~($ expressed in United States Dollars)~~
~~Note 8 - Commitments and Contingencies (continued)~~
b) Operating Lease Right-of-Use Obligations

As all the existing leases subject to the new lease standard ASC 842 ~~("Leases"~~(“Leases”) were previously classified as operating leases by the Company, they were similarly classified as operating leases under the new standard. The Company has determined that the identified operating leases did not contain non-lease components and require no further allocation of the total lease cost. Additionally, the agreements in place did not contain information to determine the rate implicit in the leases, so the Company used its incremental borrowing rate as the discount rate. The ~~Company's~~Company’s weighted average discount rate is ~~4.49%~~2.45% and the weighted average remaining lease term is 3335 months.
During the three months ended March 31, 2022, the Company entered into a new lease agreement. The lease is initially for 62 months and the initial rent is $7,642 a month. In connection with the new lease agreement the Company recorded $461,341 of right-of-use assets in exchange for right-of-use liabilities.

As of ~~June 30, 2021,~~March 31, 2022, operating lease right-of-use assets and liabilities arising from operating leases were ~~$318,393~~$830,257 and ~~$323,996,~~$843,443, respectively. During the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, cash paid for amounts included for the measurement of lease liabilities was ~~$44,059~~$55,975 and the Company recorded operating lease expense of ~~$44,355.~~$72,865.
20
Table Of Contents
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 8 – Commitments and Contingencies
b) Operating Lease Right-of-Use Obligations (continued)

The following is a schedule showing the future minimum lease payments under operating leases by years and the present value of the minimum payments as of ~~June 30, 2021.~~March 31, 2022.

2021 - remaining

$ 103,130

2022

$ 101,644

$ 206,063

2023

$ 76,422

$ 266,837

2024

$ 50,027

$ 166,837

2025

$ 5,417

$ 120,887

2026

$ 120,400

Total Operating Lease Obligations

$ 336,640

$ 881,024

Less: Amount representing interest

$ (12,644)

$ (37,581 )
Present Value of minimum lease payments

$ 323,996

$ 843,443

The ~~Company's~~Company’s office space leases are short-term and the Company has elected under the short-term recognition exemption not to recognize them on the balance sheet. During the ~~six~~three months ended ~~June 30, 2021, $37,417 was~~March 31, 2022, the Company recognized $20,854 in short-term lease costs associated with office space leases. The annual payments remaining for short-term office leases were as follows:

2021 - remaining

$ 38,855

2022

$ 38,222

$ 23,037

Total Operating Lease Liabilities

$ 77,077

$ 23,037

c) Grants Repayable

In 2010, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for €1.05 million. Per the terms of the agreement, €314,406 of the grant is to be repaid, by installments over the period from June 30, 2014 to June 30, 2023. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6% royalty on revenue, is equal to twice the amount of funding received. As of ~~June 30, 2021,~~March 31, 2022, the grant balance repayable was ~~$65,183.~~$61,026.

In 2018, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for €605,000. Per the terms of the agreement, €181,500 of the grant is to be repaid by installments over 12 years commencing in 2020. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received. As of ~~June 30, 2021,~~March 31, 2022, the grant balance repayable was ~~$127,215.~~
21
~~Table of Contents~~
~~VOL~~~~ITIONRX LIMITED~~
~~Notes to the Condensed Consolidated Financial Statements (Unaudited)~~
~~($ expressed in United States Dollars)~~
~~Note 8 - Commitments and Contingencies (continued)~~
~~c) Grants Repayable (continued)~~$119,102.

In 2020, the Company entered into an agreement with the Walloon Region government in Belgium for a research grant for €929,433. Per the terms of the agreement, €278,830 of the grant is to be repaid by installments over 15 years commencing in 2022. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 4.34% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received. As of ~~June 30, 2021,~~March 31, 2022, the grant balance repayable was ~~$55,040.~~$51,530.

In 2020, the Company entered into an agreement with the Walloon Region government in Belgium for a research grant for €495,000. Per the terms of the agreement, €148,500 of the grant is to be repaid by installments over 10 years commencing in 2023. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received. As of ~~June 30, 2021,~~March 31, 2022, the grant balance repayable was ~~$61,254.~~$57,348.
21
Table Of Contents
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 8 – Commitments and Contingencies (continued)
c) Grants Repayable (continued)

As of ~~June 30, 2021,~~March 31, 2022, the total grant balance repayable was ~~$308,692~~$289,006 and the payments remaining were as follows:

2021 - remaining

$ 0

2022

$ 46,138

$ 43,195

2023

$ 44,367

$ 41,537

2024

$ 19,253

$ 18,026

2025

$ 21,194

$ 19,842

2026

$ 26,081

Greater than 5 years

$ 177,740

$ 140,325

Total Grants Repayable

$ 308,692

$ 289,006

d) Long-Term Debt

In 2016, the Company entered into a 7-year loan agreement with Namur Invest for €440,000 with a fixed interest rate of 4.85%, maturing in December 2023. As of ~~June 30, 2021,~~March 31, 2022, the principal balance payable was ~~$220,175.~~$146,891.

In 2016, the Company entered into a 15-year loan agreement with ING for €270,000 with a fixed interest rate of 2.62%, maturing in December 2031. As of ~~June 30, 2021,~~March 31, 2022, the principal balance payable was ~~$238,224.~~
In 2017, the Company entered into a 4-year loan agreement with Namur Invest for €350,000 with a fixed interest rate of 4.00%, maturing in June 2021. As of June 30, 2021, the principal balance payable was $0.$209,267.

In 2017, the Company entered into a 7-year loan agreement with SOFINEX for up to €1 million with a fixed interest rate of 4.50%, maturing in September 2024. As of ~~June 30, 2021,~~March 31, 2022, €1 million had been drawn down under this agreement and the principal balance payable was ~~$888,857.~~$665,738.

In 2018, the Company entered into a 4-year loan agreement with Namur Innovation and Growth for €500,000 with a fixed interest rate of 4.0%, maturing in June 2022. As of ~~June 30, 2021,~~March 31, 2022, the principal balance payable was ~~$177,839.~~$42,250.

In 2019, the Company entered into a 4-year loan agreement with Namur Innovation and Growth for €500,000 with a fixed interest rate of 4.80%, maturing in September 2024. As of ~~June 30, 2021,~~March 31, 2022, the principal balance payable was ~~$553,460.~~$405,646.

On October 13, 2020, the Company entered into a 10-year loan agreement with Namur Invest for a maximum of €830,000 with fixed interest rate of 4.00%, maturing March 2031. As of March 31, 2022, the amount that has been drawn down under this agreement was €761,106, representing a principal balance payable of $844,496.
On November 23, 2021, the Company entered into a 3 ½ year loan agreement with SOFINEX for a maximum of €450,000 with fixed interest rate of 5.00%, maturing June ~~30, 2021,~~2025. As of March 31, 2022, the amount that has been drawn down under this agreement was €450,000, representing a principal balance payable of $499,304.
On February 5, 2022, the Company entered into a 9-month loan agreement with First Insurance Funding for a maximum of $620,549 with fixed interest rate of 3.57%, maturing November 2022. As of March 31, 2022, the amount that has been drawn down under this agreement was $620,549 and the principal balance payable was ~~$963,562.~~$551,599.

22
Table ofOf Contents
~~VOL~~~~ITIONRX~~VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)

~~Note~~Note 8 -– Commitments and Contingencies (continued)
d) Long-Term Debt (continued)

As of ~~June 30, 2021,~~March 31, 2022, the total balance for long-term debt payable was ~~$3,042,117~~$3,365,191 and the payments remaining were as follows:

2021 - remaining

$ 508,394

2022

$ 779,595

$ 1,250,098

2023

$ 678,071

$ 818,927

2024

$ 527,666

$ 669,827

2025

$ 145,755

$ 221,222

2026

$ 136,460

Greater than 5 years

$ 784,900

$ 598,386

Total

$ 3,424,381

$ 3,694,920

Less: Amount representing interest

$ (382,264)

$ (329,729 )
Total Long-Term Debt

$ 3,042,117

$ 3,365,191

e) Collaborative Agreement Obligations

In 2016, the Company entered into a research co-operation agreement with DKFZ in Germany for a five-year period for €400,000. As of ~~June 30, 2021, $237,029~~March 31, 2022, $221,913 is still to be paid by the Company under this agreement.

In 2018, the Company entered into a research collaboration agreement with the University of Taiwan for a three-year period for a cost to the Company of up to $2.55 million payable over such period. As of ~~June 30, 2021,~~March 31, 2022, $510,000 ~~is still to be paid by the Company under this agreement.~~
In 2019, the Company entered into a research collaboration agreement with the University of Taiwan for a two-year period to collect a total of 1,200 samples for a cost to the Company of up to $320,000 payable over such period. As of June 30, 2021, $0 is still to be paid by the Company under this agreement.

In 2019, the Company entered into a funded sponsored research agreement with the Texas A&M University ~~("TAMU"~~(“TAMU”) in consideration for the license granted to the Company for a five-year period for a cost to the Company of up to $400,000 payable over such period. As of ~~June 30, 2021, $122,123~~March 31, 2022, $18,994 is still to be paid by the Company under this agreement.

On September 16, 2020, the Company entered into a research agreement for the bioinformatic analysis of cell-free DNA fragments from whole-genome sequencing with the Hebrew University of Jerusalem for six months for a cost to the Company of €54,879. Subsequently the parties entered into an amendment to the agreement with an additional cost to the Company of €155,115. As of ~~June 30, 2021, $94,947~~March 31, 2022, $16,771 is still to be paid by the Company under the amended agreement.

As of ~~June 30, 2021,~~March 31, 2022, the total amount to be paid for future research and collaboration commitments was approximately ~~$964,099~~$767,678 and the payments remaining were as follows:

2021 - remaining

$ 842,026

2022 - 2025

$ 122,073

Total Collaborative Agreement Obligations

$ 964,099

2022 - remaining

$ 767,678

2022 - 2026

$ 0

Total Collaborative Agreement Obligations

$ 767,678

23
Table ofOf Contents
~~VOL~~~~ITIONRX~~VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)

~~Note~~Note 8 -– Commitments and Contingencies (continued)
f) Other Commitments

Volition Vet

On October 25, 2019, the Company entered into an agreement with TAMU for provision of in kind services of personnel, animal samples and laboratory equipment in exchange for a non-controlling interest of 7.5% in Volition Vet with an additional 5%, vesting in a year from the date of the agreement, giving TAMU in aggregate, a 12.5% equity interest as of such date. As of ~~June 30, 2021,~~March 31, 2022, TAMU has a 12.5% equity interest in Volition Vet.

Volition Germany

On January 10, 2020, the Company, through its wholly-owned subsidiary Belgian Volition, acquired an epigenetic reagent company, Octamer GmbH ~~("Octamer"~~(“Octamer”), based in Munich, Germany, and hired its founder for his expertise and knowledge to be passed to Company personnel. On March 9, 2020, Octamer was renamed to Volition Germany GmbH (or ~~"Volition Germany"~~“Volition Germany”).

Upon considering the definition of a business, as defined in ASC 805 ~~"Business~~“Business Combinations," ” paragraph ~~805~~-~~10-20,~~805-10-20, which is an integrated set of activities and assets that is capable of being conducted and managed for the purpose of providing a return, the Company has determined that this did not constitute a business. This is primarily due to the fact that additional inputs are needed in the form of training personnel further to produce outputs. Accordingly, the Company has treated this transaction as the hiring of a member of management, described below, rather than accounting for the transaction as a business combination.

The Company agreed to terms of the transaction on December 13, 2019 and closed on January 10, 2020. Pursuant to the transaction agreement, the Company purchased all outstanding shares of Octamer. In exchange, the Company agreed to issue 73,263 newly issued restricted shares of Company common stock valued at $333,969 (based on the $4.56 per share volume weighted trading price for the five days prior to December 13, 2019), committed to pay approximately €350,000, subject to adjustments, and agreed to pay off certain Octamer expenses leading up to the agreement (representing net liabilities of $6,535). At closing, the Company issued 73,263 restricted shares of Company common stock, paid an adjusted amount of approximately $357,000 (€321,736) and recorded a holdback liability of $55,404 (€50,000) to be paid after the holdback period of 9 months following the closing (subject to offset for breaches of representations and warranties). During the ~~three months~~year ended ~~March~~December 31, 2021, an amount of €43,152 was paid in full settlement of the amount due. The Company has no further financial obligations under the transaction agreement.

In connection with the transaction agreement, the Company also entered into a two-year Managing ~~Director's~~Director’s agreement with the founder of Octamer to continue to manage Volition Germany for a payment of €288,000 payable in equal monthly installments over such two-year period and a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of Volition ~~Germany's~~Germany’s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of five years post-closing.

~~During the three months ended March 31, 2020, the~~The Company recorded approximately $753,000 in ~~January 2020 as~~ compensation expense during the year 2020, as a result of cash paid, ~~in,~~ holdback liability, stock issued and assumption of expenses. As of ~~June 30, 2021, $85,330~~March 31, 2022, $nil is still to be paid by the Company under the Managing ~~Director's~~Director’s agreement and ~~$229~~$217 is payable under the 6% royalty ~~agreement.~~agreement on sales to date (towards the Company’s aggregate minimum royalty obligation of $134,217).

24
Table ofOf Contents
~~VOL~~~~ITIONRX~~VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)

Note 8 -– Commitments and Contingencies (continued)
f) Other Commitments ~~(continued)~~(Continued)

Volition America

On November 3, 2020, the Company entered into a professional services master agreement with Diagnostic Oncology CRO, LLC to conduct a pivotal clinical trial and provide regulatory submission and reimbursement related services. Under the terms of the agreement Diagnostic Oncology CRO, LLC will provide ad hoc consulting assistance on a project-by-project basis related to the review and assessment of existing data and information to prepare recommended intended use claims and coverage/reimbursement plans to support the preparation of FDA pre-submissions, clinical trial protocol development and study administration, and potential 510k regulatory marketing submissions of the ~~Company's~~Company’s diagnostic tests, including those proposed for use as an adjunct diagnostic tool for common and aggressive forms of ~~Non-Hodgkin's~~Non-Hodgkin’s Lymphoma. The initial projects contemplated by the agreement relating to ~~Non-Hodgkin's~~Non-Hodgkin’s Lymphoma obligate the Company to pay in aggregate of up to $2.9 million over a period of 22 months. Such payment obligations are on a project-by-project basis as deliverables are executed and subject to certain terms and conditions. Additionally, the Company may terminate the agreement or any project with or without cause upon at least 30 ~~days'~~days’ prior written notice. Unless earlier terminated, the term of the agreement is until December 31, 2025 or such later date as when all projects have been completed. As of ~~June 30, 2021, $18,344~~March 31, 2022, $9,588 is payable by Company for services rendered under the agreement.

g) Legal Proceedings

There are no legal proceedings which the Company believes will have a material adverse effect on its financial position.

h) Commitments in Respect of Corporate Goals and Performance-Based Awards
In August 2021 and October 2021 the Compensation Committee of the Board of Directors approved the granting of equity-based awards under the 2015 Stock Incentive Plan as well as cash bonuses, vesting upon achievement of certain corporate goals focused around product development and commercialization, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries.
Conditional upon the achievement by July 1, 2022 of all specified corporate goals as set forth in the minutes of the Compensation Committee, as well as continued service by the award recipient, the Company at the sole discretion of the Chief Executive Officer and the Chief Financial Officer would pay a cash bonus to such award recipient. The Company estimates the total compensation expense based on current recipients to be $805,840. As of March 31, 2022, the Company has accrued compensation expense of $601,000 based on the probable outcomes related to the prescribed performance targets.
As discussed in detail in Note 8 - Stock-Based Compensation, of the notes to consolidated financial statements contained in the Annual Report on Form 10-K for the year ended December 31, 2021, an aggregate of 1,000,000 stock options and 500,000 restricted stock units were issued under the 2015 Stock Incentive Plan in connection with the August and October 2021 grants.
As of March 31, 2022, the Company has recognized compensation expense of $941,848 in relation to such stock options and $803,207 in relation to such restricted stock units, based on the probable outcomes related to the prescribed performance targets on the outstanding awards.
25
Table Of Contents
VOLITIONRX LIMITED
Notes to the Condensed Consolidated Financial Statements (Unaudited)
($ expressed in United States Dollars)
Note 9 -– Subsequent Events

On July 14, 2021, the Board of Directors of the Company amended the terms of certain outstanding options granted pursuant to the 2011 Equity Incentive Plan such that (i) the expiration date for outstanding options to purchase up to an aggregate of 292,000 shares of the Company's common stock, granted on July 23, 2015, was extended from five yearsRSU and six months after vesting to ten years from the date of grant, or an expiration date of July 23, 2025, (ii) the expiration date for outstanding options to purchase up to an aggregate of 6,367 shares of the Company's common stock, granted on March 20, 2013, was extended from six years after vesting to ten years from the date of grant, or an expiration date of March 20, 2023, and (iii) the expiration date for outstanding options to purchase up to an aggregate of 8,151 shares of the Company's common stock, granted September 2, 2013, was extended from six years after vesting to ten years from the date of grant, or an expiration date of September 2, 2023. As a result of these amendments $452,433 will be recorded as additional options expense.
From July 1 to August 5, 2021, the Company raised aggregate net proceeds (net of broker's commissions and fees) of approximately $3,830 under the 2020 EDA through the sale of 1,157 shares of its common stock.Warrant Grants

Effective ~~August 3, 2021,~~April 4, 2022, the Company granted ~~stock options to purchase an aggregate maximum~~RSUs of ~~926,640~~32,000 shares of common stock ~~pursuant~~to employees of the Company and/or its subsidiaries in exchange for services provided to the ~~2015 Stock Incentive Plan,~~Company and/or its subsidiaries. The RSUs shall vest in two equal installments at 12 months and 24 months from the grant date, subject to ~~various designated directors, officers~~continued service, and ~~employees, with an exercise price~~will result in total compensation expense of ~~$3.40 per share. The actual number of options that are eligible for the time-based vesting is fixed based upon the timely achievement of certain pre-determined corporate milestones by~~$94,400.
Effective April 4, 2022, the Company ~~as set forth~~granted RSUs of 104,000 shares of common stock to employees of the Company and/or its subsidiaries in exchange for services provided to the Company and/or its subsidiaries. The RSUs shall vest in three equal installments at 12 months, 24 months and 36 months from the grant ~~documents. The options eligible~~date, subject to continued service, and will result in total compensation expense of $306,800.
Effective April 4, 2022, the Company granted a warrant to purchase 54,000 shares of common stock to a Company employee for ~~vesting~~services to the Company and/or its subsidiaries. This warrant shall vest in two equal installments at 12 months and 24 months from the grant date, subject to continued service and expire 10on April 4, 2028 and April 4, 2029, respectively, with an exercise price of $3.05 per share. The Company has calculated the estimated fair market value of this warrant at $80,901, using the Black-Scholes model and the following assumptions: term 3.5 years, ~~from the date of grant.~~ stock price $2.95, exercise price $3.05, 71.07% volatility, 2.53% risk-free rate, and no forfeiture rate.

~~Effective August 3, 2021,~~Subsequent to March 31, 2022, 76,250 RSUs vested and resulted in the ~~Company granted RSUs for an aggregate maximum~~issuance of ~~460,191~~56,712 shares of common stock ~~pursuant to~~(the remaining 19,538 shares of common stock were withheld for taxes and returned as authorized and unissued shares under the 2015 Stock Incentive ~~Plan, to various designated directors, officers and employees. The actual number~~Plan).
Equity Distribution Agreements
Termination of ~~RSUs that are eligible for the time-based vesting is fixed based upon the timely achievement of certain pre-determined corporate milestones by~~Equity Distribution Agreement
Effective May 7, 2022, the Company ~~as set forth in~~terminated its 2021 EDA and no further sales of the ~~grant documents. The RSUs eligible for vesting shall vest in two equal installments at 12 months and 24 months from~~Company’s common stock will be made under the ~~grant date, subject~~2021 EDA. From April 1, 2022 to ~~continued service.~~May 7, 2022, the Company made no additional sales under the 2021 EDA.

END NOTES TO FINANCIALS

2526
Table ofOf Contents

ITEM ~~2. MANAGEMENT'S~~2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF ~~OPERATIONS~~OPERATIONS.

The following discussion and analysis of our financial condition and results of operations should be read together with our Unaudited Condensed Consolidated Financial Statements and the related notes included elsewhere in this Report and in our Annual Report. This discussion and analysis contains forward-looking statements that are based on our current expectations and reflect our plans, estimates and anticipated future financial performance. These statements involve numerous risks and uncertainties, including those related to the anticipated impact on our business from, and our response to, the COVID-19 pandemic. Our actual results may differ materially from those expressed or implied by these forward-looking statements as a result of many factors, including those set forth in the section entitled ~~"Risk Factors"~~“Risk Factors” in this Report and in our Annual Report, as well as our other public filings with the SEC. Please refer to the section of this Report entitled ~~"Cautionary~~“Cautionary Note Regarding Forward-Looking ~~Statements"~~Statements” for additional information.

~~Company~~ Overview

~~VolitionRx~~Volition is a multi-national epigenetics company that applies its ~~Nucleosomics~~^TMNucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including certain cancers and ~~some other~~ diseases ~~including~~associated with NETosis such as sepsis and COVID-19, that are associated with the presence in the blood of networks of fibers released from activated neutrophils, a phenomenon known as NETosis. We hope that through earlier diagnosis we can helpCOVID-19. Our mission is to save lives and improve outcomes for millions of people and animals worldwide. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of ~~human and animals' lives throughout the world.~~life.

Our ~~assays~~blood tests are based on the science of ~~Nucleosomics~~^TMNucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily ~~fluid, since changes in these parameters are an~~fluid-an indication that disease is present. We are primarily focused on human diagnostics and monitoring but also have a subsidiary focused on animal diagnostics and monitoring.

~~Volition's approach is~~We have five key pillars of focus, all of which use the same proprietary Nu.Q^® platform to ~~investigate the epigenetic structure of chromatin and nucleosomes rather than investigating only the DNA sequence. We are continuously developing new technologies including:~~commercialize in different areas.

·
A suite of low cost Nu.Q® immunoassays that can accurately measure nucleosomes containing numerous epigenetic signals or structures, now being developed on a range of different enzyme-linked immunosorbent assay, or ELISA, platforms.Nu.Q^® Vet - cost-effective, easy-to-use cancer screening blood test for dogs and other animals

·
~~Nu.Q® Capture technology~~Nu.Q^® NETs - monitoring the immune system to isolate or enrich nucleosomes containing particular epigenetic signals or structures for a wide range of potential scientific and medical applications, e.g., the enrichment of nucleosomes of tumor origin in blood samples taken from cancer patients.save lives

·
~~The production of synthetic (recombinant)~~Nu.Q^® - detecting cancer early to save lives
·
Nu.Q^® Capture - capturing and concentrating samples for more accurate diagnosis
·
Nu.Q^® Discover - a complete solution to profiling nucleosomes containing exact defined epigenetic signals and structures, which is now in-house. These nucleosomes are used to ensure maximal accuracy of Nu.Q® immunoassay tests but also have many other applications including Research Use Only, or RUO, kits and as tools in epigenetic drug development.

~~Volition has also developed the use of the Nu.Q~~^® ~~technology~~Our research and development activities are centered in ~~veterinary applications~~Belgium, with an innovation laboratory in California, and ~~launched its first product, the Nu.Q~~^® ~~Vet Cancer Screening Test,~~additional offices in ~~the fourth quarter of 2020. We are in the process of developing additional veterinary~~Texas, London, and Singapore, where we focus on bringing our diagnostic and disease monitoring products ~~including a treatment monitoring test, a disease recurrence test and a point-of-care platform. Our extensive intellectual property portfolio includes the coverage of veterinary applications.~~to market.

Commercialization Strategy

~~Volition believes that~~We believe, given the global prevalence of cancer and diseases associated with NETosis, and the low-cost, accessible and routine nature of our tests, Nu.Q^®could potentially be used throughout the world.
We ~~plan~~have developed and are continuing to ~~work~~develop a large portfolio of intellectual property (“IP”), centered around the science of identifying and measuring nucleosomes in the bloodstream. We call this science Nucleosomics™. Our technologies have a large range of applications, both in humans and animals, to screen, diagnose, and risk stratify patients, as well as to monitor treatments, disease progression and potential remissions. While we initially focused on screening for cancer, we have broadened the range of indications our blood tests can detect to include several diseases associated with ~~partners~~NETosis, including sepsis and COVID-19, which is estimated to ~~commercialize Nu.Q~~^®be responsible for one in five deaths worldwide.

~~Commercialization will take multiple forms~~We aim to remain an IP powerhouse in ~~various markets~~the Nucleosomics™ space and ~~opportunities including, but not limited to:~~expect to monetize our IP and technologies through licensing and distribution contracts with companies with established distribution networks on a worldwide or regional basis, in both human and animal care.
To this end, on March 28, 2022, Volition entered into a license and product supply agreement with Heska Corporation, a leading global provider of advanced veterinary diagnostics. In exchange for granting Heska Corporation exclusive worldwide rights to sell the Nu.Q^® Vet Cancer Test at the point of care for companion animals, Volition received a $10 million upfront payment on signing and is eligible to receive up to an additional $18 million based upon the achievement of near and mid-term milestones. In addition, Volition has granted Heska non-exclusive rights to sell the Nu.Q^® Vet Cancer Screening Test in kit format for companion animals, through Heska’s network of central reference laboratories.
27
Table Of Contents
Following the roll-out of our Nu.Q^® Vet canine cancer screening test and Nu.Q^®Discover, the next series of products we anticipate launching are as follows:

·
~~Licensing and direct sales of the Nu.Q® Vet Cancer Screening Test.~~
a canine cancer monitoring test;

·
~~Sales of veterinary clinical products utilizing Nu.Q® Vet assays and/or Nu.Q® Capture reagents through distributor networks.~~
NETosis related screening and monitoring tests for use in sepsis and COVID-19;

·
~~Licensing of intellectual property, or IP,~~
cancer tests for ~~clinical products utilizing Nu.Q® assays and/or Nu.Q® Capture reagents.~~
·
~~Sales of clinical products utilizing Nu.Q® assays and/or Nu.Q® Capture reagents through distributor networks.~~
·
~~Licensing of IP for RUO kit sales of Nu.Q® assays and/or Nu.Q® Capture reagents.~~
·
~~Licensing of IP for laboratory developed patient testing services utilizing Nu.Q® assays and/or Nu.Q® Capture reagents.~~
·
~~Provision of direct research services~~humans in ~~the processing of samples using Nu.Q® RUO assays and/or Nu.Q® Capture.~~Non-Hodgkin’s Lymphoma, colorectal cancer and lung cancer.

26
Our Nucleosomics™ technology is transferable to multiple platforms including ELISA 96-well plates and, bead-based chemiluminescent and we are currently working on transferring our technology to the widely-utilized homogeneous immunoassay, or HIA, platform and several point of care platforms to enable rapid turnaround of results in–clinic and in the doctor’s office.
Additionally, we are working on complete nucleosome analysis with our Nu.Q^® Capture technology. The goal of this project is to investigate ways to specifically target circulating tumor DNA (“ctDNA”). The ability to enrich ctDNA will allow us to use mass spectrometry to analyze histone and DNA modifications, and to sequence DNA present around nucleosomes. This information could enable cancer diagnosis to identify the tissue of origin of a particular cancer.
~~Table of Contents~~

Developments - COVID-19 Pandemic

~~On March 11, 2020,~~Since the ~~World Health Organization designated the outbreak~~beginning of the ~~novel strain of coronavirus known as~~ COVID-19 as a global pandemic. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place orders, quarantines, significant restrictions on travel, as well as restrictions that prohibit many employees from going to work. Uncertainty with respect to the economic effects of the pandemic ~~has introduced significant volatility~~ in ~~the financial markets.~~
~~Throughout~~March 2020, ~~and the first six months of 2021,~~ we have implemented contingency planning to protect the health and well-being of our employees ~~with~~and to mitigate the ~~majority~~impacts of the pandemic on our ~~employees working remotely where possible.~~business. We have implemented travel restrictions as well as protocols limiting visitor access to our facilities, and we are following social distancing practices.
As a result of the COVID-19 pandemic, we have experienced and may continue to experience disruptions that could impact our clinical trials, including:

·
delays in enrolling patients in clinical trials;

·
delays in sample collection; and

·
diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as clinical trial sites and hospital staff supporting the conduct of our clinical trials.

The extent to which the COVID-19 pandemic will impact our business, financial condition, and results of operations in the future ~~is highly~~remains uncertain and will be affected by a number of ~~factors. These include~~factors outside of our control, including the duration and extent of the ~~COVID-19~~ pandemic, the development of new variants of the COVID-19 virus that may be more contagious or virulent than previous versions, the scope of mandated or recommended containment and mitigation measures, the effect of government stabilization and recovery efforts, and the success of vaccine distribution programs.

Liquidity and Capital Resources

We have financed our operations since inception primarily through private placements and public offerings of our common stock. As of ~~June 30, 2021,~~March 31, 2022, we had cash and cash equivalents of approximately ~~$27.9~~$23.7 million.

Net cash provided by operating activities was $3.0 million for the three months ended March 31, 2022 and net cash used in operating activities was ~~$11.6 million and $9.2~~$6.2 million for the ~~six~~three months ended ~~June 30,~~March 31, 2021, ~~and June 30, 2020,~~ respectively. The increase in cash ~~used in~~provided from operating activities for the period ended ~~June 30, 2021~~March 31, 2022 when compared to same period in ~~2020~~2021 was primarily due to ~~increased~~a $10.0 million payment received pursuant to our license and product supply agreement with Heska Corporation, partly offset by higher payroll costs, ~~reflecting growth in staff numbers,~~and higher ~~legal and professional fees in relation~~amounts paid to suppliers during the ~~registered public offering and an increase in marketing expenses.~~period.

Net cash used in investing activities was ~~$0.7~~$0.1 million and ~~$0.6~~$0.5 million for the ~~six~~three months ended ~~June 30,~~March 31, 2022 and March 31, 2021, ~~and June 30, 2020,~~ respectively. The ~~increase~~decrease was primarily due to a decrease in purchases of laboratory equipment.

Net cash provided by financing activities was ~~$20.7 million and $13.9~~$0.4 million for the ~~six~~three months ended ~~June 30, 2021~~March 31, 2022 and ~~June 30, 2020, respectively.~~net cash provided by financing activities was $20.2 million for the comparable period ended March 31, 2021. The ~~increase~~decrease in cash provided by financing activities for the period ended ~~June 30, 2021~~March 31, 2022 when compared to same period in ~~2020~~2021 was primarily due to $18.9 million in net cash received from the issuance of shares of common stock in a registered public offering in February 2021 ~~$1.2 million in cash received from the issuance of shares of common stock pursuant to the 2018 Equity Distribution Agreement~~ and ~~$1.2 million in cash received from the issuance of shares of common stock pursuant to the 2020 Equity Distribution Agreement, compared to $12.7~~$1.5 million in net cash received from the issuance of shares of common stock ~~in a registered public offering in May 2020 and $1.7 million in cash received from~~under our ATM facility during the ~~issuance of shares of common stock pursuant to the 2018 Equity Distribution Agreement. For additional information on the "at the market offering program," refer to Note 6,~~ ~~Common Stock - Equity Distribution Agreements,~~ ~~of the Notes to Condensed Consolidated Financial Statements.~~period ended March 31, 2021.

2728
Table ofOf Contents

The following table summarizes our approximate contractual payments due by year as of ~~June 30, 2021.~~March 31, 2022.

Approximate Payments (Including Interest) Due by Year
Approximate Payments (Including Interest) Due by Year
Approximate Payments (Including Interest) Due by Year

Total

2021 (Remaining)

2022 - 2025

2026 +

Total

2022 (Remaining)

2023 - 2026

2027 +

Description

$

$

$

$

$

$

$

$

Finance Lease Obligations

699,740

36,917

256,467

406,356

604,242

44,760

238,718

320,764

Operating Lease Obligations

413,717

141,985

271,732

-

904,061

229,100

674,961

-

Grants Repayable

308,692

-

130,952

177,740

289,006

43,195

105,486

140,325

Long-Term Debt

3,424,381

508,394

2,131,087

784,900

3,694,920

1,250,098

1,846,436

598,386

Collaborative Agreements Obligations

964,099

842,026

122,073

-

767,678

767,678

-

-

Total

5,810,629

1,529,322

2,912,311

1,368,996

6,259,907

2,334,831

2,865,601

1,059,475

We intend to use our cash reserves to ~~predominantly~~ fund further research and development ~~activities.~~activities and launch new products. We do not currently have ~~any substantial source of~~sufficient revenues to cover our annual expenses and expect to rely on ~~additional~~financing our operations in future ~~financing,~~periods, mainly through the sale of equity or debt securities, ~~or the sale of~~and licensing rights, to provide sufficient funding to execute our strategic plan. ~~There is~~However, there can be no assurance that we will be successful in raising ~~further funds.~~additional funds, or that we will be able to do so on terms that are satisfactory to us.

In the event that additional financing is delayed, we will prioritize the maintenance of our research and development personnel and facilities, primarily in Belgium, and the maintenance of our patent rights. In such instance, the completion of clinical validation studies and regulatory approval processes for the purpose of bringing products to the ~~IVD and veterinary~~in vitro diagnostics markets would be delayed. In the event of an ongoing lack of financing, it may be necessary to discontinue operations, which will adversely affect the value of our common stock.

We have not attained profitable operations on an ongoing basis and are dependent upon obtaining financing to pursue any extensive activities. For these reasons, our auditors stated in their report on our audited financial statements for the fiscal year ended December 31, ~~2020~~2021 an explanatory paragraph regarding factors that raise substantial doubt that we will be able to continue as a going concern.

2829
Table ofOf Contents

Results of Operations

Comparison of the ~~Three Months~~Three-Months Ended ~~June 30, 2021~~March 31, 2022 and ~~June 30, 2020~~March 31, 2021.

The following table sets forth our results of operations for the three months ended on ~~June 30,~~March 31, 2022 and March 31, 2021, ~~and June 30, 2020, respectively:~~respectively.

Three Months Ended June 30,

Increase

Increase

Three Months Ended March 31,

Increase

Increase

2021

2020

(Decrease)

(Decrease)

2022

2021

(Decrease)

(Decrease)

$

$

$

%

$

$

$

%

Royalty

-

1,872

(1,872)

(100%)

Services

60,254

-

60,254

>100 %
Product

24,782

3,322

21,460

>100%

53,957

25,530

28,427

>100 %
Total Revenues

24,782

5,194

19,588

>100%

114,211

25,530

88,681

>100 %

Research and development

3,649,469

3,492,845

156,624

4%

3,590,053

3,873,079

(283,026 )

(7
%)
General and administrative

1,816,599

1,508,836

307,763

20%

2,602,152

1,810,160

791,992

44 %
Sales and marketing

459,371

215,891

243,480

>100%

1,598,983

427,401

1,171,582

>100 %

Total Operating Expenses

5,925,439

5,217,572

707,867

14%

7,791,188

6,110,640

1,680,548

28 %

Grant income

391,532

90,946

300,586

>100%
(Loss) Gain on disposal of fixed assets

(26,166)

93,202

(119,368)

(100%)

Interest income

492

7,741

(7,249)

(94%)

2

1,721

(1,719 )

(100
%)
Interest expense

(39,688)

(22,604)

17,084

76%

(41,032 )

(42,181 )

1,149

(3
%)
Total Other Income

326,170

169,285

156,885

93%
Total Other Income / (Expenses)

(41,030 )

(40,460 )

(570 )

1 %

Net Loss

(5,574,487)

(5,043,093)

531,394

11%

(7,718,007 )

(6,125,570 )

1,592,437

26 %

Revenues

Our operations are ~~still predominantly in the~~transitioning from a research and development focused stage ~~and we had limited revenues~~to a commercialization stage. Revenues during the three-months ended March 31, 2022 were $114,211, compared with $25,530 for the three-months ended March 31, 2021. The main source of ~~$24,782 and $5,194~~revenue during the three months ended ~~June 30, 2021~~March 31, 2022 was services revenues from our Nu.Q^®Discover offering and ~~June 30, 2020, respectively.~~product revenues from sales of the Nu.Q^®Vet Cancer Screening Test and H3.1 kits. The ~~main~~primary source of ~~revenues~~revenue during the ~~three months~~three-months ended ~~June 30,~~March 31, 2021 was direct sales of the Nu.Q^®Vet Cancer Screening Test via the Gastrointestinal Laboratory at Texas A&M University.

Operating Expenses

Total operating expenses increased to ~~$5.9~~$7.8 million ~~from $5.2 million during~~for the three months ended ~~June 30,~~March 31, 2022 from $6.1 million for the three months ended March 31, 2021, ~~and June 30, 2020, respectively,~~ as a result of the factors described below.

2930
Table ofOf Contents

Research and Development Expenses

Research and development expenses ~~increased~~declined to $3.6 million from $3.9 million and for the ~~three months~~three-months ended ~~June 30,~~March 31, 2022 and March 31, 2021, ~~from $3.5 million for the three months ended June 30, 2020.~~respectively. This ~~increase~~decline was primarily related to lower direct and other research and development expenses, partly offset by higher personnel expenses ~~offset~~and stock-based compensation. The number of full-time equivalent (“FTE”) personnel we employed in this division increased by ~~lower research and collaboration costs during~~10 to 55 compared to the prior year period.

Three Months Ended June 30,

Three Months Ended March 31,

2021

2020

Change

2022

2021

Change

$

$

$

$

$

$

Personnel expenses

1,536,490

1,212,777

323,713

1,775,719

1,492,444

283,275

Stock-based compensation

25,347

114,872

(89,525)

191,167

90,127

101,040

Direct research and development expenses

1,664,941

1,936,125

(271,184)

1,331,283

1,642,619

(311,336 )
Other research and development

161,830

(50,770)

212,600

145,333

402,017

(256,684 )
Depreciation and amortization

260,861

279,841

(18,980)

146,551

245,872

(99,321 )
Total research and development expenses

3,649,469

3,492,845

156,624

3,590,053

3,873,079

(283,026 )

General and Administrative Expenses

General and administrative expenses increased to ~~$1.8~~$2.6 million from ~~$1.5~~$1.8 million for the ~~three months~~three-months ended ~~June 30,~~March 31, 2022 and March 31, 2021, ~~and June 30, 2020,~~ respectively. This increase was primarily due to higher personnel expenses and stock-based compensation during the period. The FTE personnel number within this division increased by 5 to 19 compared to the prior year period.

Three Months Ended June 30,

Three Months Ended March 31,

2021

2020

Change

2022

2021

Change

$

$

$

$

$

$

Personnel expenses

776,911

511,652

265,259

1,173,180

617,071

556,109

Stock-based compensation

240,855

204,055

36,800

444,801

333,866

110,935

Legal and professional fees

490,777

507,732

(16,955)

505,853

560,778

(54,925 )
Other general and administrative

275,499

230,146

45,353

347,384

266,927

80,457

Depreciation and amortization

32,557

55,251

(22,694)

130,934

31,518

99,416

Total general and administrative expenses

1,816,599

1,508,836

307,763

2,602,152

1,810,160

791,992

Sales and Marketing Expenses

Sales and marketing expenses increased to ~~$0.5~~$1.6 million from ~~$0.2~~$0.4 million for the ~~three months~~three-months ended ~~June 30,~~March 31, 2022 and March 31, 2021, ~~and June 30, 2020,~~ respectively. This increase was primarily due to higher personnel expenses, ~~during the period~~stock-based compensation and direct marketing and professional ~~fees.~~ fees during the period. The FTE personnel number within this division increased by 11 to 18 compared to the prior year period.

Three Months Ended June 30,

2021

2020

Change

$

$

$

Personnel expenses

231,082

110,753

120,329

Stock-based compensation

71,542
��

41,713

29,829

Direct marketing and professional fees

156,747

63,425

93,322

Total sales and marketing expenses

459,371

215,891

243,480

~~Other Income~~
For the three months ended June 30, 2021, the Company's other income was $326,170 compared to other income of $169,285 for the three months ended June 30, 2020. The increase in other income was mainly due to grant income.
~~Net Loss~~
For the three months ended June 30, 2021, the Company's net loss was $5.6 million in comparison to a net loss of $5.0 million for the three months ended June 30, 2020. The change was primarily a result of the factors described above.
30
~~Table of Contents~~
~~Comparison of the Six Months Ended~~ ~~June 30, 2021 and June 30, 2020~~
~~The following table sets forth our results of operations for the six months ended on June 30, 2021 and June 30, 2020, respectively:~~

Six Months Ended June 30,

Increase

Percentage Increase

2021

2020

(Decrease)

(Decrease)

$

$

$

$

Royalty

-

2,112

(2,112)

(100)%
Product

50,312

3,626

46,686

>100%
Total Revenues

50,312

5,738

44,574

>100%

Research and development

7,522,547

7,387,811

134,736

2%
General and administrative

3,626,759

3,212,358

414,401

13%
Sales and marketing

886,772

489,845

396,927

81%

Total Operating Expenses

12,036,078

11,090,014

946,064

9%

Grant income

391,532

98,870

292,662

>100%
(Loss) / Gain on disposal of fixed assets

(26,167)

93,202

(119,369)

(100)%
Interest income

2,213

46,155

(43,942)

(95)%
Interest expense

(81,869)

(56,383)

25,486

45%

Total Other Income

285,709

181,844

103,865

57%

Net Loss

(11,700,057)

(10,902,432)

797,625

7%
~~Revenues~~
Our operations are still predominantly in the research and development stage and we had limited revenues of $50,312 and $5,738 during the six months ended June 30, 2021 and June 30, 2020, respectively. The main source of revenues during the six months ended June 30, 2021 was direct sales of the Nu.Q^®~~Vet Cancer Screening Test via the Gastrointestinal Laboratory at Texas A&M University.~~
~~Operating Expenses~~
~~Total operating expenses increased to $12.0 million from $11.1 million for the six months ended June 30, 2021 and June 30, 2020, respectively as a result of the factors described below.~~

Three Months Ended March 31,

2022

2021

Change

$

$

$

Personnel expenses

1,017,091

184,137

832,954

Stock-based compensation

279,063

131,349

147,714

Direct marketing and professional fees

290,643

111,915

178,728

Depreciation and amortization

12,186

-

12,186

Total sales and marketing expenses

1,598,983

427,401

1,171,582

31
Table ofOf Contents

~~Research and Development Expenses~~
Research and development expenses increased to $7.5 million for the six months ended June 30, 2021, from $7.4 million for the six months ended June 30, 2020. This increase in overall research and development expenditures was primarily related to increased personnel expenses offset by lower antibody and research and collaboration costs during the period.

Six Months Ended June 30,

2021

2020

Change

$

$

$

Personnel expenses

3,028,929

2,506,925

522,004

Stock-based compensation

115,474

177,291

(61,817)
Direct research and development expenses

3,243,601

3,364,563

(120,962)
Other research and development

627,810

966,105

(338,295)
Depreciation and amortization

506,733

372,927

133,806

Total research and development expenses

7,522,547

7,387,811

134,736

~~General and Administrative Expenses~~
General and administrative expenses increased to $3.6 million from $3.2 million for the six months ended June 30, 2021 and June 30, 2020, respectively. This increase was primarily due to higher personnel expenses and legal fees during the period.

Six Months Ended June 30,

2021

2020

Change

$

$

$

Personnel expenses

1,393,982

1,040,831

353,151

Stock-based compensation

574,721

311,320

263,401

Legal and professional fees

1,055,435

927,589

127,846

Other general and administrative

538,546

820,441

(281,895)
Depreciation and amortization

64,075

112,177

(48,102)
Total general and administrative expenses

3,626,759

3,212,358

414,401

~~Sales and Marketing Expenses~~
Sales and marketing expenses increased to $0.9 million from $0.5 million for the six months ended June 30, 2021 and June 30, 2020, respectively. This increase was primarily due to higher personnel expenses and direct marketing and professional fees during the period.

Six Months Ended June 30,

2021

2020

Change

$

$

$

Personnel expenses

415,219

261,698

153,521

Stock-based compensation

202,891

64,698

138,193

Direct marketing and professional fees

268,662

163,449

105,213

Total sales and marketing expenses

886,772

489,845

396,927

Other Income (Expenses)

For the ~~six months~~three-months ended ~~June 30, 2021,~~March 31, 2022, the ~~Company's~~Company’s other ~~income was $285,709~~expenses were $41,030 compared to other ~~income~~expenses of ~~$181,844~~$40,460 for the ~~six months~~three-months ended ~~June 30, 2020.~~March 31, 2021. This increase in other ~~income~~expenses was primarily ~~due~~related to ~~grant income.~~the decrease in interest earned during the period.
32
~~Table of Contents~~

Net Loss

For the ~~six months~~three-months ended ~~June 30, 2021,~~March 31, 2022, the ~~Company's~~Company’s net loss was ~~$11.7~~$7.7 million, an increase of approximately $1.6 million in comparison to a net loss of ~~$10.9~~$6.1 million for the ~~six months~~three-months ended ~~June 30, 2020.~~March 31, 2021. The change was a result of the factors described above.

Going Concern

We have not attained profitable operations on an ongoing basis and are dependent upon obtaining external financing to continue to pursue our operational and strategic plans. For these reasons, management has determined that there is substantial doubt that the business will be able to continue as a going concern without further financing.

Off-Balance Sheet Arrangements

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

Future Financings

We may seek to obtain additional capital through the sale of debt or equity securities if we deem it desirable or necessary. These sales may include the sale of equity securities from time to time through ~~our "at~~an “at the market offering ~~program" with Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc.~~program” under ~~the~~an Equity Distribution ~~Agreement dated November 10, 2020 (see Note 6 of the notes to the condensed consolidated financial statements).~~Agreement. However, we may be unable to obtain such additional capital when needed, or on terms favorable to us or our stockholders, if at all. If we raise additional funds by issuing equity securities, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or such equity securities may provide for rights, preferences or privileges senior to those of the holders of our common stock. If additional funds are raised through the issuance of debt securities, the terms of such securities may place restrictions on our ability to operate our business.

Critical Accounting Policies and Estimates

Our interim condensed consolidated financial statements and ~~related condensed~~accompanying notes have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, applied on a consistent basis. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. A summary of these policies is included in the notes to our financial statements. In general, ~~management's~~management’s estimates are based on current facts, historical experiences, information from third party professionals and various other factors that it believes to be reasonable under the circumstances. Actual results could differ materially and adversely from those estimates made by management. To the extent there are material differences between the estimates and the actual results, future results of operations could be affected.

Recently Issued Accounting Pronouncements

The Company has implemented all applicable new accounting pronouncements that are in effect. The Company does not believe that there are any other applicable new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

3332
Table ofOf Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company and are not required to disclose this information.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Disclosure controls and procedures are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the ~~SEC's~~SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by our company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our Principal Executive and Principal Financial Officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer have concluded, as they previously concluded as of December 31, ~~2020,~~2021, that our disclosure controls and procedures were not effective as of ~~June 30, 2021,~~March 31, 2022, because of material weaknesses in our internal control over financial reporting, as referenced below and described in detail in our Annual ~~Report for the year ended December 31, 2020.~~Report.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

~~The~~In our Annual Report, the deficiencies identified ~~involve~~involved the segregation of duties in some areas of finance, the oversight in information technologies, where certain processes may affect the internal controls over financial reporting, and the monitoring of review controls with respect to accounting for complex transactions.finance.

~~During the first half of 2021, our management, with oversight from our audit committee, has implemented the following remediation~~We have already taken steps ~~to help address and mitigate some of the underlying~~towards remediating such deficiencies ~~which gave rise to the previously disclosed material weaknesses and to improve our internal control over financial reporting:~~including:

·
hired an additional full-time ~~accounting resources and financial planning and analysis resources~~Business Controller in Belgium with an appropriate ~~levels~~level of experience;

·
hired an experienced financial planning and analysis manager to implement forecasting and budgeting processes;
·
changed ~~certain~~ organizational reporting lines and reallocated certain responsibilities to improve segregation of duties; and

·
~~reallocated responsibilities across the finance and accounting organization to ensure that the appropriate level of knowledge and experience is applied based on complexity of tasks being undertaken.~~implemented additional review procedures at each month end close.

We intend to take additional measures around certain processes we have identified which we believe once implemented in conjunction with the completed actions above will mitigate and remedy this weakness.
We also intend to take additional steps to ~~mitigate~~further strengthen the ~~issues identified.~~control environment. Such measures include but may not be limited to:

·
recruitment of a specialist in Human Resources to recommend and implement relevant policies and processes that will strengthen the control environment;
·
further strengthening our internal processes and reviews, including formal documentation thereof;

·
preparation of risk-control matrices to identify key risks and develop and document policies to mitigate those risks; and

·
engaging additional resources if necessary to help us assess, document, design and implement control activities related to internal control over financial reporting.

As we continue to evaluate and test the remediation plan outlined above, we may also identify additional measures to address the material weaknesses or modify certain of the remediation procedures described above. We also may implement additional changes to our internal control over financial reporting as may be appropriate in the course of remediating the material weakness. Management, with the oversight of our audit committee, will continue to take steps necessary to remedy the material weakness to reinforce the overall design and capability of our control environment.

33
Table Of Contents
Changes in Internal Control over Financial Reporting

Except for the ongoing remediation of the material weaknesses in internal controls over financial reporting noted above, no changes in our internal control over financial reporting were made during the fiscal quarter ended ~~June 30, 2021,~~March 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations of the Effectiveness of Disclosure Controls and Internal Controls

Our management, including our Principal Executive Officer and Principal Financial Officer, does not expect that our disclosure controls and internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control.

The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions; over time, a control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

34
Table ofOf Contents

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In the ordinary course of business, we may be subject to claims, counter claims, lawsuits and other litigation of the type that generally arise from the conduct of our business. We know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our directors, officers or any affiliates, or any registered or beneficial stockholders, is an adverse party or has a material interest adverse to our interest.

ITEM 1A. RISK FACTORS

There have been no material changes in our assessment of risk factors affecting our business since those presented in Part I, Item 1A of our Annual Report.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Sales of Unregistered Securities

None.

Repurchase of Equity Securities

No equity securities were repurchased during the ~~second~~first quarter of ~~2021.~~2022.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

~~None.~~Termination of Equity Distribution Agreement
Effective May 7, 2022, the Company terminated its Equity Distribution Agreement dated September 24, 2021 with Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. (the “2021 EDA”) and no further sales of the Company’s common stock will be made under the 2021 EDA. From inception through May 7, 2022, the Company raised aggregate net proceeds (net of brokers’ commissions and fees) of approximately $0.7 million under the 2021 EDA through the sale of 193,600 shares of its common stock.

35
Table ofOf Contents

ITEM 6. EXHIBITS

Incorporated by Reference
Exhibit
Number

Exhibit Description

Form

File No.

Exhibit

Filing
Date

Filed
Herewith
10.1†

License and Supply Agreement between Belgian Volition and Heska Corporation, dated March 28, 2022.
X

~~10.1#~~
~~2015 Stock Incentive Plan, as amended~~
~~8-K~~
~~001-36833~~
~~10.1~~
~~06/22/21~~
~~10.2#†~~
Consulting Services Agreement by and between Volition Germany and 3F Management SPRL (Gaetan Michel), dated January 29, 2021; First Amendment dated February 1, 2021; Second Amendment dated May 1, 2021.
~~10-Q~~
~~001-36833~~
~~10.7~~
~~05/11/21~~

31.1

Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.

X

X

31.2

Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.

X

32.1*

Certifications of Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of ~~2002~~2002..

101.INS

XBRL Instance Document.

X
101.SCH

XBRL Taxonomy Extension Schema Document.

X
101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document.

X
101.LAB

XBRL Taxonomy Extension Label Linkbase Document.

X
101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document.

X
101.DEF

XBRL Taxonomy Extension Definition Linkbase Document.

X
104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

X

~~# Indicates a management contract or compensatory plan or arrangement.~~
† Portions of this exhibit are redacted pursuant to Item 601(a)(6) and/or Item (b)(10)(iv) under Regulation S-K. The registrant agrees to furnish supplementally any omitted schedules to the SEC upon request.
* The certifications attached as Exhibit 32.1 accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed "filed" by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant's
†
Portions of this exhibit are redacted pursuant to Item 601(a)(6) and/or Item (b)(10)(iv) under Regulation S-K. The registrant agrees to furnish supplementally any omitted schedules to the SEC upon request.
*
The certifications attached as Exhibit 32.1 accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant’s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.

36
Table ofOf Contents

SSIGNATURES~~IGNATURES~~

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VOLITIONRX LIMITED

Dated: ~~August~~May 11, ~~2021~~2022
By:
/s/ Cameron Reynolds

Cameron Reynolds

President and Chief Executive Officer
(Authorized Signatory and Principal Executive Officer)

Dated: ~~August~~May 11, ~~2021~~2022
By:
/s/ Terig Hughes

Terig Hughes
Chief Financial Officer and Treasurer
(Authorized Signatory and Principal Financial
~~Financial~~ and Accounting Officer)

37

PART I	FINANCIAL INFORMATION		PAGE

Item 1.	FINANCIAL STATEMENTS (UNAUDITED)	4

Item 2.	~~MANAGEMENT'S~~MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS		2627

Item 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK		3433

Item 4.	CONTROLS AND PROCEDURES		3433

PART II	OTHER INFORMATION

Item 1.	LEGAL PROCEEDINGS		35

Item 1A.	RISK FACTORS		35

Item 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS		35

Item 3.	DEFAULTS UPON SENIOR SECURITIES		35

Item 4.	MINE SAFETY DISCLOSURES		35

Item 5.	OTHER INFORMATION		35

Item 6.	EXHIBITS		36

SIGNATURES			37

	Number of	Weighted Average
	Warrants	Exercise Price ($)
Outstanding at December 31, 2020	175,000		2.75
Granted	310,000		4.52
Outstanding at June 30, 2021	485,000		3.88

Exercisable at June 30, 2021	125,000		2.47

			Weighted Average
	Number of Warrants		Exercise Price ($)
Outstanding at December 31, 2021		485,000		3.88
Granted		-		0
Outstanding at March 31, 2022		485,000		3.88

Exercisable at March 31, 2022		485,000		3.88

				Weighted Average
				Remaining		Proceeds to
Number	Number	Exercise		Contractual		Company if
Outstanding	Exercisable		Price ($)		Life (Years)		Exercised ($)
125,000	125,000		2.47		0.83		308,750
50,000	-		3.45		4.67		172,500
185,000	-		4.90		5.59		906,500
125,000	-		3.95		5.51		493,750
485,000	125,000						1,881,500

			Weighted
			Average
	Number of		Exercise
	Options		Price ($)
Outstanding at December 31, 2020		4,278,619		4.00
Granted		40,000		3.60
Exercised		(277,634)		4.19
Outstanding at June 30, 2021		4,040,985		3.99

Exercisable at June 30, 2021		3,990,985		3.99

			Weighted Average
	Number of Options		Exercise Price ($)
Outstanding at December 31, 2021		5,027,518		3.87
Granted		-		0
Exercised		-		0
Expired/Cancelled		0		0
Outstanding at March 31, 2022		5,027,518		3.87

Exercisable at March 31, 2022		3,937,518		4.00

	Number of RSUs		Share Price ($)
Outstanding at December 31, 2020		67,500		3.47
Granted		185,000		3.37
Vested		(31,250)		3.56
Cancelled		(15,000)		3.30
Outstanding at June 30, 2021		206,250		3.38

	Number of			Weighted Average
	RSUs			Share Price ($)
Outstanding at December 31, 2021		810,750			3.33
Granted		38,000			2.81
Vested/Settled		(15,000	)		3.59
Cancelled		-			0
Outstanding at March 31, 2022		833,750			3.30

2021 - remaining	$	36,917
2022	$	65,234	$	44,760
2023	$	63,745	$	59,680
2024	$	63,744	$	59,679
2025	$	63,744	$	59,679
2026			$	59,680
Greater than 5 years	$	406,356	$	320,764
Total	$	699,740	$	604,242
Less: Amount representing interest	$	(87,067)	$	(70,896	)
Present value of minimum lease payments	$	612,673	$	533,346

2021 - remaining	$	103,130
2022	$	101,644	$	206,063
2023	$	76,422	$	266,837
2024	$	50,027	$	166,837
2025	$	5,417	$	120,887
2026			$	120,400
Total Operating Lease Obligations	$	336,640	$	881,024
Less: Amount representing interest	$	(12,644)	$	(37,581	)
Present Value of minimum lease payments	$	323,996	$	843,443

2021 - remaining	$	38,855
2022	$	38,222	$	23,037
Total Operating Lease Liabilities	$	77,077	$	23,037

2021 - remaining	$	0
2022	$	46,138	$	43,195
2023	$	44,367	$	41,537
2024	$	19,253	$	18,026
2025	$	21,194	$	19,842
2026			$	26,081
Greater than 5 years	$	177,740	$	140,325
Total Grants Repayable	$	308,692	$	289,006

2021 - remaining	$	508,394
2022	$	779,595	$	1,250,098
2023	$	678,071	$	818,927
2024	$	527,666	$	669,827
2025	$	145,755	$	221,222
2026			$	136,460
Greater than 5 years	$	784,900	$	598,386
Total	$	3,424,381	$	3,694,920
Less: Amount representing interest	$	(382,264)	$	(329,729	)
Total Long-Term Debt	$	3,042,117	$	3,365,191

2021 - remaining	$	842,026
2022 - 2025	$	122,073
Total Collaborative Agreement Obligations	$	964,099

2022 - remaining	$	767,678
2022 - 2026	$	0
Total Collaborative Agreement Obligations	$	767,678

	·	A suite of low cost Nu.Q® immunoassays that can accurately measure nucleosomes containing numerous epigenetic signals or structures, now being developed on a range of different enzyme-linked immunosorbent assay, or ELISA, platforms.Nu.Q^® Vet - cost-effective, easy-to-use cancer screening blood test for dogs and other animals
	·	~~Nu.Q® Capture technology~~Nu.Q^® NETs - monitoring the immune system to isolate or enrich nucleosomes containing particular epigenetic signals or structures for a wide range of potential scientific and medical applications, e.g., the enrichment of nucleosomes of tumor origin in blood samples taken from cancer patients.save lives
	·	~~The production of synthetic (recombinant)~~Nu.Q^® - detecting cancer early to save lives
	·	Nu.Q^® Capture - capturing and concentrating samples for more accurate diagnosis
	·	Nu.Q^® Discover - a complete solution to profiling nucleosomes containing exact defined epigenetic signals and structures, which is now in-house. These nucleosomes are used to ensure maximal accuracy of Nu.Q® immunoassay tests but also have many other applications including Research Use Only, or RUO, kits and as tools in epigenetic drug development.

	·	~~Licensing and direct sales of the Nu.Q® Vet Cancer Screening Test.~~ a canine cancer monitoring test;
	·	~~Sales of veterinary clinical products utilizing Nu.Q® Vet assays and/or Nu.Q® Capture reagents through distributor networks.~~ NETosis related screening and monitoring tests for use in sepsis and COVID-19;
	·	~~Licensing of intellectual property, or IP,~~ cancer tests for ~~clinical products utilizing Nu.Q® assays and/or Nu.Q® Capture reagents.~~
	·	~~Sales of clinical products utilizing Nu.Q® assays and/or Nu.Q® Capture reagents through distributor networks.~~
	·	~~Licensing of IP for RUO kit sales of Nu.Q® assays and/or Nu.Q® Capture reagents.~~
	·	~~Licensing of IP for laboratory developed patient testing services utilizing Nu.Q® assays and/or Nu.Q® Capture reagents.~~
	·	~~Provision of direct research services~~humans in ~~the processing of samples using Nu.Q® RUO assays and/or Nu.Q® Capture.~~Non-Hodgkin’s Lymphoma, colorectal cancer and lung cancer.

	·	delays in enrolling patients in clinical trials;
	·	delays in sample collection; and
	·	diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as clinical trial sites and hospital staff supporting the conduct of our clinical trials.

Approximate Payments (Including Interest) Due by Year	Approximate Payments (Including Interest) Due by Year									Approximate Payments (Including Interest) Due by Year

		Total		2021 (Remaining)		2022 - 2025		2026 +			Total		2022 (Remaining)		2023 - 2026		2027 +
Description		$		$		$		$			$		$		$		$
Finance Lease Obligations			699,740		36,917		256,467		406,356			604,242		44,760		238,718		320,764
Operating Lease Obligations			413,717		141,985		271,732		-			904,061		229,100		674,961		-
Grants Repayable			308,692		-		130,952		177,740			289,006		43,195		105,486		140,325
Long-Term Debt			3,424,381		508,394		2,131,087		784,900			3,694,920		1,250,098		1,846,436		598,386
Collaborative Agreements Obligations			964,099		842,026		122,073		-			767,678		767,678		-		-
Total			5,810,629		1,529,322		2,912,311		1,368,996			6,259,907		2,334,831		2,865,601		1,059,475

	Three Months Ended June 30,				Increase		Increase		Three Months Ended March 31,						Increase			Increase
	2021		2020		(Decrease)		(Decrease)		2022			2021			(Decrease)			(Decrease)
	$		$		$		%		$			$			$			%

Royalty		-		1,872		(1,872)	(100%)
Services										60,254			-			60,254			>100	%
Product		24,782		3,322		21,460		>100%		53,957			25,530			28,427			>100	%
Total Revenues		24,782		5,194		19,588		>100%		114,211			25,530			88,681			>100	%

Research and development		3,649,469		3,492,845		156,624		4%		3,590,053			3,873,079			(283,026	)	(7		%)
General and administrative		1,816,599		1,508,836		307,763		20%		2,602,152			1,810,160			791,992			44	%
Sales and marketing		459,371		215,891		243,480		>100%		1,598,983			427,401			1,171,582			>100	%

Total Operating Expenses		5,925,439		5,217,572		707,867		14%		7,791,188			6,110,640			1,680,548			28	%

Grant income		391,532		90,946		300,586		>100%
(Loss) Gain on disposal of fixed assets		(26,166)		93,202		(119,368)	(100%)
Interest income		492		7,741		(7,249)	(94%)			2			1,721			(1,719	)	(100		%)
Interest expense		(39,688)		(22,604)		17,084		76%		(41,032	)		(42,181	)		1,149		(3		%)
Total Other Income		326,170		169,285		156,885		93%
Total Other Income / (Expenses)										(41,030	)		(40,460	)		(570	)		1	%

Net Loss		(5,574,487)		(5,043,093)		531,394		11%		(7,718,007	)		(6,125,570	)		1,592,437			26	%

	Six Months Ended June 30,				Increase		Percentage Increase
	2021		2020		(Decrease)		(Decrease)
	$		$		$		$
Royalty		-		2,112		(2,112)		(100)%
Product		50,312		3,626		46,686		>100%
Total Revenues		50,312		5,738		44,574		>100%

Research and development		7,522,547		7,387,811		134,736		2%
General and administrative		3,626,759		3,212,358		414,401		13%
Sales and marketing		886,772		489,845		396,927		81%

Total Operating Expenses		12,036,078		11,090,014		946,064		9%

Grant income		391,532		98,870		292,662		>100%
(Loss) / Gain on disposal of fixed assets		(26,167)		93,202		(119,369)		(100)%
Interest income		2,213		46,155		(43,942)		(95)%
Interest expense		(81,869)		(56,383)		25,486		45%

Total Other Income		285,709		181,844		103,865		57%

Net Loss		(11,700,057)		(10,902,432)		797,625		7%

	·	hired an additional full-time ~~accounting resources and financial planning and analysis resources~~Business Controller in Belgium with an appropriate ~~levels~~level of experience;
	·	hired an experienced financial planning and analysis manager to implement forecasting and budgeting processes;
	·	changed ~~certain~~ organizational reporting lines and reallocated certain responsibilities to improve segregation of duties; and
	·	~~reallocated responsibilities across the finance and accounting organization to ensure that the appropriate level of knowledge and experience is applied based on complexity of tasks being undertaken.~~implemented additional review procedures at each month end close.

	·	recruitment of a specialist in Human Resources to recommend and implement relevant policies and processes that will strengthen the control environment;
	·	further strengthening our internal processes and reviews, including formal documentation thereof;
	·	preparation of risk-control matrices to identify key risks and develop and document policies to mitigate those risks; and
	·	engaging additional resources if necessary to help us assess, document, design and implement control activities related to internal control over financial reporting.

	VOLITIONRX LIMITED

Dated: ~~August~~May 11, ~~2021~~2022	By:	/s/ Cameron Reynolds
		Cameron Reynolds
		President and Chief Executive Officer
		(Authorized Signatory and Principal Executive Officer)


Dated: ~~August~~May 11, ~~2021~~2022	By:	/s/ Terig Hughes
		Terig Hughes
		Chief Financial Officer and Treasurer
		(Authorized Signatory and Principal Financial ~~Financial~~ and Accounting Officer)